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Autosomal Dominant Polycystic Disease 
Autosomal Dominant Polycystic Disease (ADPKD) is the most common genetic 
disorder causing chronic kidney disease with a prevalence of 1:400-1:1000.1 Affected 
patients have numerous fluid-filled cysts in the kidneys. Over time, the cysts 
progressively increase in size and become surrounded by fibrosis. The enlarging cysts 
compress surrounding normal nephrons resulting in a decline of renal function. It is a 
typically adult onset disease first manifesting after the age of 30, though occasionally it 
manifests as an early onset disease in infants.2-4 Most patients develop end stage renal 
failure (ESRF) in the fifth or sixth decade. Besides ESRF, ADPKD patients may suffer 
from other complications, like cysts in the liver, the pancreas, abnormalities in the 
arterial blood vessels as well as hypertension and renal adenoma.5 About 60% of the 
patients have back, flank, or abdominal pain that may lead to physical impairment.6 This 
pain may be due to kidney enlargement. Other causes of pain are cystic hemorrhage, 
infection, or renal stone. There is no cure for ADPKD and no therapy is yet clinically 
proven to retard cyst enlargement.7 
Genetics
In 85% of ADPKD patients, mutations are found in the PKD1 gene and 10-15% of the 
cases in the PKD2 gene.8 The PKD1 gene is located on chromosome 16 and spans 52 kb 
containing 46 exons.9 The PKD2 gene is found on chromosome 4 and is a smaller gene 
spanning 68 kb of genomic DNA and containing 15 exons.10,11 A high level of allelic 
heterogeneity is found for both genes.12 The fact that PKD1 gene is more prone to 
mutations may be explained by the presence of several duplicates of the first part of the 
gene, which show 95-97% homology to the PKD1 gene. These pseudogenes probably 
promote gene conversion.13 Moreover, long polypurine-polypyrimidine tracts are 
present, which are capable to form multiple non-B-DNA structures and PKD1 gene is 
larger than PKD2 gene.14 All these factors may predispose the gene to mutagenesis.
The ADPKD patients show widespread variations in disease severity ranging from rare 
cases showing massively enlarged cystic kidneys in utero,4,15 through more typical 
presentation with end stage renal disease (ESRD) in the fifth or sixth decade, to cases 
with sufficient kidney function until old age.12,16 Some studies indicate that the location 
of the mutation in the PKD1 gene may influence the severity of the disease.17-19 Patients 
with mutations in the 5′ region of PKD1 have more severe disease and are more likely to 
have intracranial aneurysms than patients with 3′ mutations. Also patients with mutation 
in PKD2 show a milder phenotype compared to the PKD1 disease. This is due to the 
development of more cysts in PKD1 disease at an early age.20,21 Furthermore, 
environmental factors, smoking and diet have shown to influence the progression towards 
chronic renal failure.12,22 However, variation especially found between family members, 
may also be due to modifying genes which might directly affect the function of 
polycystins, cyst formation or the clinical factors associated with disease progression.23 
Recent data suggest that also missense variants in the other allele can modify the 
phenotype.24  
Several studies show that renal cysts may develop from loss of heterozygosity. However, 
dosage reduction (<20%) of the protein in two Pkd1 animal models with hypomorph-
ic alleles indicates that cysts can develop even if the protein is not completely lost.25,26 
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Furthermore, in transgenic mice overexpressing the PKD1 and PKD2 transgenes in the 
kidneys revealed renal cystic disease comparable to the human ADPKD phenotype.27,28 
These studies suggest that an imbalance in the expression of polycystins affects their 
function and lead to the development of PKD.
Polycystins
The gene products of the PKD1 and PKD2 are polycystin-1 (PC1) and polycystin-2 
(PC2), respectively (Figure 1). PC1 consist of 4302 amino acids weighting 450 kDa.29 It 
has the structure of a receptor or adhesion molecule with a large extracellular N terminal 
segment of 3000 amino acids, 11 transmembrane domains and a relatively small intra- 
cellular C terminus, which has a coiled coil domain. The extracellular N terminus contains 
many domains, which are also present in receptors that mediate cell-cell and cell-matrix 
interactions suggesting the same function for PC1.30,31 Furthermore, PC1 is involved in 
mechano-sensing and cellular signaling.32-34 PC1 interacts with PC2 through a coiled-coil 
domain in the C-terminal portion and with multiple other proteins at different extracel-
lular and intracellular sites.35
The extracellular part of PC1 contains a G-protein-coupled receptor proteolytic site. 
Cleavage at this site results in a C-terminal fragment and an N-terminal fragment. Pkd1-
null mice die in utero, but mice with a mutation preventing cleavage of PC1 protein 
survive to post natal day 28 with enlarged cystic kidneys.36-40 This may mean that cleaved 
PC1 is critical for maintenance of tubular integrity. In addition, proteolytic cleavage of 
the cytoplasmic carboxy-terminal part of the protein generates fragments directly 
involved in signal transduction.41 PC1 is expressed during development in many organs 
e.g. kidneys, pancreas, liver, lung, intestines, brain, reproductive organs, placenta, 
thymus, hart, skeletal muscle, and blood vessels.42,43 
Figure 1. Predicted protein structure of polycystin-1 and polycystin-2.
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After birth the expression of PC1 decreases in the kidney except for the collecting ducts 
and distal part of the nephrons, which show the highest expression level of PC1 in the 
kidney.43,44 The subcellular localization of PC1 is apical at the plasma membrane, at cell 
adhesion complexes, desmosomes, and the primary cilium.34,45 
PC2 contains 968 amino acids with a molecular weight of 110 kDa. It has homology to 
the last six transmembrane segments of PC1.46 The C-terminal part contains a calcium-
binding motif (EF-hand) and coiled-coil domain, which may interact with the coiled coil 
domain of PC1 as well as other proteins.35,47 It is also a hexaspanner protein, which 
resembles the α-subunit of voltage-activated calcium and sodium channels. Therefore, it 
is suggested that PC2 is an ion channel especially permeable to calcium ions.46 PC2 has 
been shown to localize predominantly to the endoplasmic reticulum, but also to the 
plasma membrane, primary cilium, centrosome, and mitotic spindles in dividing cells.34,48,49
PC1 and PC2 are expressed in almost the same tissues. However, the expression of PC2 
does not decrease after birth and expression in adult kidneys is overlapping but not 
identical to PC1 expression, i.e. PC2 is mainly present in the medullary thick ascending 
limb and distal cortical tubules.42,50 
Pathogenesis of Cyst Formation
The polycystins are essential to maintain the normal structure of the tubular epithelium 
in the kidney. Reduction or increase of one of these proteins below or above a critical 
threshold results in cystogenesis, characterized by proliferation of the epithelium, 
excessive secretion of solute and fluid into the cysts, remodeling of the extracellular 
matrix and aberrant mechano-sensing via the cilia. The exact molecular mechanisms 
responsible for these phenotypic changes are not known, but our knowledge is increasing.
Proliferation and Apoptosis
In normal human kidneys, renal tubular epithelial proliferation is strongly reduced soon 
after birth. In adult kidneys, cell proliferation is mainly seen during tissue repair after 
ischemic or toxic damage. In ADPKD kidneys, proliferation is increased in the cyst-
lining epithelia.51 Several studies suggest that proliferation accelerates the cyst forma-
tion during kidney development or tissue repair after injury. Conditional knockout mice 
of Pkd1 at various time points have shown that the timing of Pkd1 inactivation deter-
mines the progression of the disease.52,53 Kidney development in newborn mice is not 
yet completed and epithelial cells show an increased proliferation rate compared to adult 
kidneys. Inactivation of Pkd1 in the early neonatal period results in rapidly progressive 
cystic disease, whereas later inactivation causes much slower cyst development. Pkd1 
inactivation in adult mice, results in the slowest onset of cyst formation. This suggests 
that a certain threshold of cell proliferation must be surpassed. Furthermore, renal in-
jury accelerates cyst formation in the kidneys of Pkd1-deletion mice and Kif3a knockout 
mice.54,55,56 These findings suggest that cyst growth in adults with PKD may be affected by 
environmental factors such as kidney infection, or exposure to toxins. Individual varia-
tion in exposure to these environmental factors may contribute to the variation in severity 
of PKD that is observed between members of the same family who have inherited the 
identical gene mutation.22
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Many pathways that are involved in epithelial cell proliferation are activated in PKD, 
including, mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) 
and mammalian target of rapamycin (mTOR).57,58 In addition, several studies suggest that 
the polycystins can directly regulate the cell cycle. PC1 was reported to activate JAK2/
STAT-1 signaling and upregulate p21 (a cell cycle inhibitor).59 PC2 was reported to bind 
Id2, and prevent its translocation to the nucleus and suppression of p21, thereby 
activating cell cycle progression.60 Indeed, p21 levels have been found to be decreased in 
human and animal PKD tissues.61 Furthermore, Pkd1 prevents immortalized 
proliferation of renal epithelia through the induction of p53 and the activation of JNK 
signaling.62 Increased levels of cAMP are a common finding in the kidneys of many PKD 
models.35,63 While under normal conditions cAMP inhibits mitogen-activated protein 
kinase signaling and cell proliferation, in PKD or in conditions of calcium deprivation it 
stimulates cell proliferation. The abnormal proliferative response to cAMP is 
directly linked to the low intracellular Ca2+ concentrations, which is suggested to be 
directly linked to deletion or overexpression of polycystins.57,63-66 Upregulation of the 
vasopressin V2 receptor and high circulating vasopressin levels may contribute to the 
increased cAMP levels.67,68 Furthermore, a bioactive lipid with the same biochemical and 
biological properties as forskolin, a potent adenylyl cyclase agonist, has been isolated and 
identified within the cyst fluid.69 
Several studies have shown that increased tubular cell proliferation go along with 
increased apoptosis in PKD.58,70,71 Apoptosis was detected in kidneys of humans with 
ADPKD regardless of renal function, but not in normal kidneys.51,71 In these studies, 
apoptosis was detected in cystic and noncystic tubules in human polycystic kidneys 
suggesting that it may be associated with the progressive loss of normal nephrons in PKD. 
Furthermore, several Pkd models show increased apoptosis like, Pck and Han:SPRD 
rats.72,73 Deletion of anti-apoptotic genes Bcl-2 and AP-2a as well as overexpressing the 
pro-apoptotic c-Myc (SBM mice) results in renal cysts formation.74-76 Other studies show 
a link between PKD1 and apoptosis: the Pkd1 hypomorphic mouse Pkd1L3/L3 showed 
increased apoptosis and overexpression of PKD1 has been shown to induce G0/G1 phase 
arrest in cell cycle and an increased apoptosis in cancer cell lines.26,77 Furthermore, PC1 
knockdown in MDCK cells is associated with increased rates of proliferation and 
apoptosis. This is accompanied by resistance to anoikis, inducing apoptosis by loss of 
cell anchorage.78 
Extra-Cellular Matrix Remodeling
Renal interstitial fibrosis is common in human and animal models of PKD. It is
characterized by infiltration of inflammatory cells, fibroblasts, and an abnormal 
accumulation of extracellular matrix (ECM) components resulting into progressive loss 
of normal renal tissue. Many of these ECM molecules, like collagen and matrix-
degrading enzymes and inhibitors of metalloproteinases (MMPs), are necessary for the 
remodeling of basement membranes and the surrounding ECM. ADPKD cyst epithelia 
are surrounded by a basement membrane with increased expression of matrix 
components like fibronectin, collagen, MMPs and proteoglycans.79-82 A recent study 
showed in zebrafish that a combined knockdown of the Pkd1 and Pkd2 resulted in a 
persistent expression of multiple collagen mRNAs, and low levels of collagen-
crosslinking inhibitors, implicating that polycystins are involved in the modulation of 
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collagen expression and assembly.83 Furthermore, ECM components, which show 
increased expression in cystic kidneys, like laminin-5 and periostin, can actively 
contribute to epithelial cell proliferation and cyst growth, resulting into a positive 
feedback.84,85 Cyst-lining epithelia and interstitial fibroblasts are responsible for the 
production of these structural proteins, enzymes and growth factors. Transforming growth 
factor b (TGFb), a pro-fibrotic growth factor, is expressed in renal cystic and interstitial 
cells.79 In these studies, TGFb/Smad2 signaling was increased in PKD mouse models.
Fluid Secretion
Tubular epithelial cells have the ability to secrete as well as to reabsorb solutes and fluid. 
Normally, absorptive flux is more than the secretory flux. Sodium chloride reabsorption 
in collecting duct principal cells is driven by low intracellular sodium concentration 
generated by basolateral Na-K-ATPase. Sodium chloride enters the apical membrane 
through the epithelial sodium and chloride channels (Figure 2A). Water enters the cells 
across the luminal membrane through vasopressin-sensitive aquaporin-2 channels. Cystic 
epithelial cells are different from normal collecting duct principal cells. Chloride enters 
across basolateral NaKCC1 cotransporters, driven by the sodium gradient generated by 
basolateral Na-K-ATPase, and exits across apical protein kinase A (PKA)-stimulated 
cystic fibrosis transmembrane conductance regulator (CFTR).86-88 Active accumulation 
of chloride within the cyst lumen drives sodium and water secretion down transepithelial 
potential and osmotic gradients (Figure 2B).
Figure 2. The absortive and secretory flux in normal collecting duct cells (A) and cystic cells 
(B). 
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Several lines of evidence suggest an important role of this mechanism in cyst formation. 
Inhibitors of CFTR and basolateral membrane ion channels retard growth of MDCK cysts 
in collagen gel, and inhibit 8-Br-cAMP stimulated tubule dilation in metanephric organ 
cultures.89,90 In addition, no tubular dilation was observed in metanephric organ cultures 
from Cftr-/- mice in response to 8-Br-cAMP.91 Finally, both CFTR and NKCC1 expression 
was observed in the cysts of ADPKD patients.86,88,92 Furthermore, it is shown that Pkd1 
can inhibit CFTR surface expression and activation suggesting that upon decreasing Pkd1 
expression, CFTR surface localization would increase.93 This model for cyst fluid 
secretion requires a paracellular pathway sealed by tight junctions impermeable to 
chloride. If it is not, the transepithelial Cl- gradient generated by active secretion would be 
lost by back-leakage of Cl-, reducing the driving force for Na+ and fluid secretion. Indeed, 
the composition of tight junctions is altered in cystic epithelia.94
Cilia
It is suggested that PKD arises from abnormalities in the primary cilium.95 The primary 
cilium is a hairlike structure that is found on most cells in the body. It consists of a bundle 
of microtubules, called the axoneme, surrounded by a membrane that is continuous with 
the cell membrane (Figure 3). The primary cilium is anchored in the cell body by the basal 
body, which also functions as a centriole during mitosis. Renal epithelial cells have cilia, 
which project into the tubular lumen and are believed to function as mechano-sensors of 
urine flow. Fluid flows over the apical surface of the cells, bending the primary cilium, 
and producing an increase in intracellular calcium concentration, which influence cell 
signaling pathways.96 According to this model, PC1 extracellular domain functions as an 
extracellular sensing antenna on the cilia. PC1 regulates the PC2 ion channel through its 
intracellular interaction with PC2. Cilia activation induces Ca2+ influx via PC2 which is 
further increased through the release of Ca2+ from the endoplasmatic reticulum. 
Treatment of wild type cells with blocking antibodies against PC2 also inhibits the flow-
dependent increase in intracellular Ca2+ concentration.34,97 These findings suggest that 
PC1 and PC2 have a mechanosensory function in renal cilia that is coupled to 
intracellular Ca2+ concentration. 
Figure 3. Schematic representation of the primary cilia. 
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PKD is believed to be associated with a dysfunction of primary cilia. PC1, PC2, and 
fibrocystin (protein encoded by the gene mutated in recessive PKD) as well as proteins that 
are mutated in other cystic kidney diseases, such as nephronophthisis and Bardet-Biedl 
syndrome, are located in the primary cilium and/or basal body.98,99 Furthermore, mouse 
models harbouring mutations involved in cilia formation for example Ift88 (Tg737), 
Kif3a and Cpk develop cystic kidneys.99-102
Cilia might also regulate orientation of cell division known as planar cell polarity (PCP). 
A recent study determined PCP in the kidneys of the PKD models, PCK rats and HNF-
1β knockout mice.103 Using lineage tracing and staining of mitotic cells, it was found 
that cells in wild type renal tubules divide along an axis that is approximately parallel to 
the longitudinal axis of the tubule, resulting in tubular elongation without changing the 
diameter of the tubule. In contrast, in pre-cystic tubules, the orientation of cell division 
is randomized. This contributes to tubular dilatation, resulting into cyst formation. These 
results suggest that abnormalities in PCP are present during early stages of cystogenesis. 
The defects in PCP that are found in PKD may a result of dysfunctional or abnormal 
primary cilium. Deletion of ciliogenic gene Kif3a results in randomized orientation of cell 
division in pre-cystic tubules that lack primary cilia, indicating aberrant PCP.55 Similar 
findings have been observed in mice with collecting duct-specific inactivation of another 
ciliogenic gene, Ift20.104 These results suggest that abnormalities in primary cilia induce 
disorientation in PCP that lead to PKD.
Extra-Renal Cysts 
Polycystic liver disease is the most common extrarenal manifestation among ADPKD 
patients with a frequency of 77% among patients over 60 years.105 It is likely that in time, 
somatic mutations and other harmful events accumulate and trigger liver cyst forma-
tion.106 Liver cysts arise by excessive proliferation and dilatation of biliary ductules. Inter-
estingly, PC1 and 2 expression is also detected in the hepatic biliary ductular cells.42,107,108 
Hepatic cysts are more prevalent and have a larger volume in women than in men. 
Especially in women who have multiple pregnancies or who have used oral contraceptive 
drugs or oestrogen replacement therapy.109 Indeed it is reported that estrogen receptors 
are expressed in the epithelium lining the hepatic cysts, and estrogens stimulate hepatic 
cyst-derived cell proliferation.110
Although polycystic liver disease is asymptomatic, but as the lifespan of patients with 
polycystic kidney disease has been lengthened with dialysis and transplantation, 
symptoms have become more common. Symptoms can result from mass effect or from 
complications related to the cysts, like dyspnoea, early satiety, gastro-oesophageal reflux, 
mechanical low-back pain, hepatic venous outflow obstruction, compression of the 
inferior vena cava, portal-vein, or bile-duct. Symptomatic cyst complications include cyst 
haemorrhage and infection. 
Pancreatic cysts are less common in ADPKD patients with a frequency of 9% over 30 
years.111 These patients show only a few cysts in the pancreas which are almost always 




Intracranial aneurysms, aortic and cervicocephalic artery dissections (partial rupture of 
vessel wall) are associated with ADPKD. These patients show a 10-fold higher 
prevalence of cerebral aneurysms compared to the general population and among 
ADPKD patients with a family history for aneurysms the prevalence is about 27%.112,113 
For aortic aneurysms, a few clinical studies suggest a prevalence varying from 1-10% 
in ADPKD.114-116 Rupture of the vessel wall causes a 35–55% risk of combined severe 
morbidity and mortality. 
Aneurysm is a vascular disorder in which weakness of the artery causes a localized 
dilatation. This is caused by an imbalanced matrix turnover favoring matrix accumulation 
and disruption of elastin lamellae, a sheath of highly flexible material providing strength 
and elasticity to the vessel wall. Aneurysms are usually asymptomatic until rupture
occurs, followed by lethal haemorrhage.
 
PC1 is expressed in vascular smooth muscle cells as well as endothelial cells. 36,42,117 In 
these cells, PC1 is found at intercellular junctions and cell-matrix junctions. Furthermore, 
Pkd1 and Pkd2 knock-out mouse models die at embryonic days 13.5-14.5 from a primary 
cardiovascular defect.36-38,118 These embryos show edema, focal vascular leaks and 
haemorrhage, suggesting that Pkd1 and 2 are essential for normal vessel development. 
Based on these data, it was suggested that PC1 stabilizes adhesion of cells to each other 
or to the extracellular matrix during and after angiogenesis, thereby maintaining vascular 
integrity.37 However, mouse models with reduced expression of Pkd1 show aneurysms 
but with an overall normal vessel wall structure, suggesting that a low expression level 
of PC1 is enough for normal vessel development but not for vessel wall maintenance.80 
Hypertension is very common in ADPKD, with a prevalence of 50–70% and it is observed 
before reduction in glomerular filtration rate.119,120 Furthermore, hypertension occurs at an 
earlier age in ADPKD patients than in the general population.121 Renal structural changes 
in patients with ADPKD have an important role in the pathogenesis of hypertension. 
Adult patients with ADPKD and hypertension had significantly greater renal volume than 
patients with normal blood pressure.122 Immunohistochemical studies of human ADPKD 
kidneys have shown hyperplasia of renin-secreting cells of the juxtaglomerular 
apparatus, which suggests chronic stimulation of the Renin-Angiotensin-Aldosterone-
System (RAAS) in ADPKD.123 Furthermore, high levels of renin were found in cyst fluid 
of ADPKD patients.124 These findings suggest that activation of the RAAS as a result 
of cyst expansion and local renal ischemia has an important role in the development of 
hypertension in this disease.
Besides RAAS, the cilia are also involved in blood pressure regulation. In endothelial 
primary cilia, PC1 and PC2 are involved in fluid shear sensing and nitric oxide release, 
thus contributing to vasodilation in response to an increase in blood flow. Aberrant 
expression of PC2 on cilia could increase blood pressure because of inability to 
synthesize nitric oxide in response to an increase in shear stress.125 Furthermore, 
polycystins are also expressed in arterial smooth muscle cells, which respond to 
intraluminal pressure that causes wall stretch. An increase in intraluminal pressure causes 
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myocyte constriction via the stretch-activated cation channels (SACs). Aberrant PC1/
PC2 ratio reduces SAC activity and the arterial myogenic tone since PC2 inhibits channel 
opening, while PC1 reverses this inhibition.126 
Aim of Thesis
In this thesis we analyzed the pathogenetic sequence of renal cyst and aneurysm 
formation in PKD mouse models. In chapter two, we studied cyst formation in Pkd1nl/nl on 
the C57Bl6/J background by analyzing tubular cell proliferation, apoptosis, extracellular 
matrix remodeling, and the expression the Na+K+2Cl- co-transporter (NKCC1). These 
mice presented with a rapidly progressive phenotype with mild fibrosis and, in time, cyst 
formation was nephron segment-dependent. Interestingly, the expression of Na+K+2Cl- 
co-transporters (NKCC1) was also segment-dependent. 
In chapter three, we described TGFb signaling during cysts formation and progression 
in C57Bl6/J-Pkd1nl/nl and inducible Pkd1-deletion mice.79 TGFb signaling is activated 
at the progressive stages of the disease and coincides with mild fibrosis and increased 
expression of TGFb target genes. These results suggest that the TGFb signaling pathway 
is probably not implicated in initial steps of cyst formation, but indicate an important role 
during cyst progression and in fibrogenesis of progressive ADPKD.  
In chapter four, we have characterized dissecting aneurysm formation in the hypomorphic 
mouse model, Pkd1nl/nl with reduced Pkd1 transcripts in the kidneys and aorta.80 Lowering 
of Pkd1 transcription levels induces degenerative alterations in both the intima and media 
of the aorta resulting into a dissecting aneurysm, indicating a direct association between 
Pkd1 and vessel wall integrity.
In chapter five, we study the effect of selective disruption of Pkd1 in vascular smooth 
muscle cells (SMCs).127 Remarkably, we did not find any spontaneous gross structural 
blood vessel abnormalities in mice with somatic Pkd1 disruption in SMCs or 
simultaneous disruption of Pkd1 in SMCs and endothelial cells (ECs). However, cyst 
formation was detected in pancreas, liver and kidneys. Furthermore, SM22-Pkd1del/del mice 
significantly showed reduced decrease in heart rate upon Angiotensin II-induced 
hypertension. These findings further demonstrate in vivo, that adaptation to hypertension 
is altered in SM22-Pkd1del/del mice. 
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Abstract
Autosomal dominant polycystic kidney disease is characterized by progressive cyst 
formation in the kidneys. We previously described the hypomorphic Pkd1nl/nl mouse 
model that expresses reduced levels of Pkd1 transcripts. On a mixed 129/Ola;C57Bl6/J 
genetic background, these mice developed polycystic kidneys with variable severity and 
lifespan. Here we present the model on C57Bl6/J genetic background. These mice 
presented with a rapidly progressive phenotype and, in time, cyst formation was 
nephron segment-dependent, starting with cysts formed in proximal tubules. 
Interestingly, the expression Na+K+2Cl- co-transporters (NKCC1), which is involved in 
transepithelial Cl- secretion, also demonstrate a segment-dependent pattern. Cystogenesis 
is accompanied with proliferation but hardly with apoptosis. In time activation of TGFß 
signaling increases as well as the expression of genes involved in extra-cellular matrix 
synthesis and remodeling (PAI-1, ColI, EDA-Fn, Mmp-2, u-Pa, SerpinF1). In parallel, 
also the mRNA levels encoding potential urinary biomarkers increase (Lcn2, Sgp-2, 
Ptgds, C3). A careful analysis for extra-renal manifestations revealed no manifestations 
in addition to previously reported dissecting aneurysms. These results indicate that the 
C57Bl6/J-Pkd1nl/nl mice model seems to reflect the phenotype of patients with early onset 
PKD as result to two hypomorphic mutations. 
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of end-
stage renal disease characterized by bilateral renal cyst formation and a progressive loss 
of normal kidney tissue that can lead to chronic renal failure. The disease is caused by 
mutations in PKD1, which encodes polycystin-1, and/or PKD2, which encodes poly-
cystin-2. These proteins are involved in mechano-sensing, cellular signaling, and cell-
cell/cell-matrix interactions.1-4 
In general, ADPKD patients carry one germ-line mutation and one normal PKD1 or 
PKD2 allele. Renal cysts develop from somatic inactivation of PKD1 or PKD2 by a 
‘two-hit’ mechanism.5 In addition, haploinsufficiency, stochastic fluctuations in PKD1 or 
PKD2 gene dosage below a tissue-specific threshold, may suffice to cause cyst 
formation.6 Importantly, recent studies indicate that the picture can be more complex, 
since several families have been reported with non- or incompletely penetrant alleles of 
PKD1.7,8 At a heterozygous state, they produce no or a very mild phenotype. However, 
when these hypomorphic alleles are inherited at a homozygous state, or in trans with 
another mutation, they can produce mild atypical or severe polycystic kidney disease. 
Evenmore, two hypomorphic PKD1-alleles were identified in trans in patients with an 
ARPKD-like renal cystic phenotype identified in utero, in families with no history of 
PKD.8
We previously described the hypomorphic Pkd1nl/nl mouse model of polycystic kidney 
disease that expresses Pkd1 at a reduced level.9 Pkd1nlnl mice are viable and develop 
severe PKD, different from mice with homozygous inactivation of Pkd1 or Pkd2, which 
die in utero due to severe cyst formation in the kidneys and extra-renal defects and/or 
abnormalities of the placental labyrinth.10-16 The severity of the phenotype and lifespan 
varied on a mixed genetic background, 129Ola and C57Bl6/J.9 In the current study, we 
studied the ontogeny of cyst formation in Pkd1nl/nl on C57Bl6/J background, and 
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analyzed cell proliferation, apoptosis, the expression of the ion co-transporter Na+K+2Cl- 
co-transporter (NKCC1) and extracellular matrix remodeling, as well as the expression of 
genes involved in tissue remodeling and cyst formation. In addition, a careful analysis for 
extra-renal manifestations revealed no additional manifestations to previously reported 
dissecting aneurysms.17
Results
Pkd1 Expression in C57Bl6/J-Pkd1nl/nl Kidneys
In this study, we analyzed mice bred with C57Bl6/J for 12 generations in order to obtain 
an almost 100% C57Bl6/J genetic background. Mice were sacrificed at postnatal days 
1, 7, 10, 13, 21, and 28. Using reverse transcriptase multiplex ligation-dependent probe 
amplification (RT-MLPA), we determined the level of normal and total Pkd1 transcripts. 
In general, the level of normal Pkd1 transcripts was decreased to approximately 20% of 
the levels in wild type mice (Figure 1A). In wild type mice, Pkd1 expression decreased 
as the mice got older, a pattern reflected in the sum of mutant and normal transcripts in 
the C57Bl6/J-Pkd1nl/nl mice, only at days 21 and 28, when the kidneys presented a severe 
cystic phenotype, the expression of the mutant Pkd1 transcripts was slightly increased, 
resulting in 1.5-fold higher levels of total Pkd1 transcripts at day 28 (data not shown). 
Normal Pkd1 expression dipped at day 10. The number of mice evaluated at this age, 
however, was too small to allow for conclusions. Expression of Pkd2 was not 
significantly different between mutants and controls, although at 28 days expression was 
significantly higher compared to 13 days (Figure 1B).  Since Pkd1 and the tuberous 
sclerosis 2 (Tsc2) gene are located, tail-to-tail, only 63 base pairs apart, we analyzed Tsc2 
gene expression.18 At all ages Tsc2 gene expression was lower (Figure 1C). 
Cyst Formation in C57Bl6/J-Pkd1nl/nl Kidneys
Cyst formation was evaluated from postnatal day 1 until the age of 1 month, when the 
kidneys reached a largely cystic state (Table 1, Figure 2). Nephron segment-specific 
markers were used to identify the origin of renal cysts. Antibodies against megalin were 
used to stain the proximal tubules,19 antibodies against uromodulin were used to label 
the thick ascending limb of Henle and distal convoluted tubules20 and antibodies against 
anti-aquaporin-2 identified collecting ducts.21
In newborn mice, at days 1 and 3, many dilated proximal tubules were present in the 
inner cortex (Figure 2, A and C, and Figure 3A). At day 7, proximal cysts were found in 
the cortico-medullary region between the mesenchymal cells (Figure 2E and Figure 3B). 
A few of these cysts exhibited a partial loss of megalin staining (Figure 3B, arrow). The 
nephrogenic zone was normal.22 In the medulla, many small cysts and dilatations started 
to develop in the collecting ducts at day 7 (Figure 3C). The cysts and dilatations were 
derived from distal tubules or collecting ducts. A few dilatations were negative for all 
markers used. From day 10 onward, the epithelial cysts occupied the entire cortex and 
medulla, and they increased in number and size until the age of 3 and 4 weeks (Figure 2, 
G, I, K, and M). At days 10 and 13, the majority of cysts in the cortex and medulla were 
derived from the collecting ducts (Figure 3D). Some dilated distal tubules were present 
at day 13. At days 21 and 28, most cysts were positive for distal tubule or collecting duct 
epithelial markers (Figure 3E). 
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Figure1. Relative mRNA transcription levels of Pkd1, Pkd2, Tsc2, SMAD2-target genes and 
biomarkers genes in kidneys from wild type and C57Bl6/J-Pkd1nl/nl mice. The expression of 
each gene versus reference gene Hprt  has been normalized to the mean of wild type mice at day 
28, which has been set to 1. The expression levels of the wild type and mutant mice of the same 
age were compared with an unpaired 2-tailed t-test.  (A) The 5’ Pkd1 PCR amplifies normal Pkd1 
transcripts. The expression level of normal Pkd1 transcription in the kidney of Pkd1nl/nl mice shows 
a reduction to approximately 20% compared to wild type. (B) Expression of Pkd2 was not signifi-
cantly different between mutants and controls. (C) At all ages Tsc2 gene expression was lower in 
mutant kidneys compared to wild types. (D-I) At early neonatal stages expression of all SMAD2-
target genes is not significantly different compared to wild types. At days 21 and 28, however, 
transcript levels are increased in mutants compared to wild types.(D) Collagen1 (ColI). (E) EDA-
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•        Kidneys not fully developed
•        Proximal dilated tubules in inner-cortex. 
•        Proliferation not increased and no indication of apoptosis
Day 
7
• Large fusiform proximal cysts in cortico-medullary junction
• Numerous small cysts in medulla from collecting duct origin
• Proliferation not increased and no indication of apoptosis
Day 
10-13
• Entire kidney occupied by cysts 
• Most cysts originate from collecting ducts and few cysts originate 
              from distal tubules.
• No glomerular cysts
• Proliferation not increased and no indication of apoptosis 
• Accumulation of collagen around few cysts
Day 
21 -28
• Progressive cystic kidneys with many large cysts and a few normal 
              tubules.
• Proliferation increased in tubules and cysts at the cortico-medullary 
               junction at day 21 
• Apoptosis in large cysts.
• Accumulation of collagen around many cysts
Furthermore, some cysts stained for both of these markers. A few cysts were positive for 
megalin, whereas other cysts did not stain for any epithelial marker. The latter group of 
cysts may be proximal cysts that have lost megalin expression, as previously reported 
for the Cy/+ rat.23 Some cysts were fusiform in shape (Figure 3D, arrow); however, the 
most inner part of the papilla exhibited relatively normal renal tissue with a few dilated 
collecting ducts. Glomerular cysts were not found at any age. We did not observe any 
gender differences. 
Extra-renal Manifestations
In order to determine extra-renal abnormalities, we analyzed the pancreas and 
livers of three C57Bl6/J-Pkd1nl/nl mice aged one month and did not observe cysts in 
these organs. We did not observe any ductal plate malformations or portal fibrosis. 
We previously reported dissecting aneurysms in the aorta and mesenteric artery of these 
mice.24
fibronectin (EDA-Fn). (F) Matrix metalloproteinase-2 (Mmp-2). (G) Plasminogen activator inhibi-
tor 1 (Pai-1). (H) Urokinase-type plasminogen activator (uPA) is reduced compared to wild type 
starting from day 10. (I) Expression of another inhibitor in plasmin synthesis, alpha-2 antiplasmin 
(Serpin F1), is increased. (J-L) Three biomarkers which monitor disease progression were ana-
lyzed. The expression levels of these genes were increased with disease progression. (J) Neutrophil 
gelatinase-associated lipocalin (Lcn2). (K) Sulfated glycoprotein-2 (Sgp-2). (L) Complement C3 
(C3). Black diamonds: wild type; white diamonds: C57Bl6/J-Pkd1nl/nl  *:p=0.01-0.05;  **: p=0.01-
0.001; ***p<0.001
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Figure 2. Time course of 
development of polycystic 
kidney disease in C57Bl6/J-
Pkd1nl/nl mice from day 1 
until day 28. 
At young ages (day 1-7) 
dilated tubules and a few 
cysts can be observed, while 
at older ages, from day 10 on, 
the entire kidney is occupied 
with cysts. At days 21 and 
28, the kidneys reach a very 
progressive stage with loss of 
normal renal tissue. A, C, E, 
G, I, K, M: C57Bl6/J-Pkd1nl/nl 
kidneys, and B, D, F, H, J, L, 
N: wild type kidneys.
Haematoxylin Eosin staining. 
Bar=100mm  
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Figure 3. Immunohistochemical 
Analysis of renal cysts in C57Bl6/J-
Pkd1nl/nl mice.
(A) 3-days-old kidney shows dilated 
tubules in the cortex, which stain for 
megalin. (B) At day 7, the small cysts 
in this region show focal expression of 
megalin (B arrow). (C) At day 7 dilated 
tubules and small cysts start to develop 
in the medulla. Most of them express 
aquaporin-2. (D) At day 13 the majority 
of cysts in cortex and medulla show 
expression of aquaporin-2. Some of 
these cysts are fusiform (arrow D). (E) 
Cysts originating from distal tubules, 
expressing uromodulin, are at 21. (F) 
Cysts showing many proliferating cells 
at day 21. The region of this cyst is the 
cortex. (G) In the cortico-medullary 
region of wild type kidney almost no 
proliferating cells are present, day 21. 
(H) However, dilated tubules in the 
same region of the mutant kidney about 
10% of the cells are mitotic, day 21. (I) 
Collagen, stained by Sirius red, in a wild 
type 4-weeks-old kidney. The 
collagen fibers are concentrated around 
the tubules (arrowhead). (J) Collagen in 
a C57Bl6/J-Pkd1nl/nl 4-weeks-old-
kidney. Interstitial collagen 
accumulation is found around cysts 
(asterisk). (K) The 21-days-old wild 
type kidney shows basolateral 
localization of NKCC1 in the outer 
medulla (arrow). (L) The same 
basolateral pattern for NKCC1 is found 
in tubules and cysts of C57Bl6/J-
Pkd1nl/nl kidneys at the same region and 
age (arrow). 
A, B: megalin, C, D: aquaporin-2, E: 
Uromodulin, F-H: Ki67, I-J: Sirius red. 
K-L: NKCC1.  Bar=100mm. 
Proliferation, Apoptosis, and Extracellular Matrix Accumulation in C57Bl6/J-Pkd1nl/nl 
Kidneys
A variety of studies suggest that increased proliferation and/or apoptosis is essential for 
cyst formation.25-28 Antibodies against Ki67, which stains mitotic cells, and antibodies 
against active caspase-3, which detects the terminal phase of apoptosis, were used. The 
proliferation index (PI) was determined at days 7, 13, and 21 (Figure 4). Proliferation 
was highest in tubules and small cysts in the cortex and cortico-medullary region of both 
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Figure 4. Proliferation index (PI) in wild type and C57Bl6/J-Pkd1nl/nl kidneys.
(A) PI values in different nephron segments of (dilated) tubules and small cysts in mutant kidneys 
compared to wild type kidneys. Cortico-medullary regions at days 13 and 21 in mutants show a 
significantly different PI compared to wild type kidneys (at day13 wild type mean 39.58 ± 3.91 
versus mutant mean 22.92 ± 2.94 p=0.04; at day 21 wild type mean 0.68 ± 0.48 versus mutant mean 
9.73 ± 3.81 p=0.049). (B) PI values in (dilated) tubules and small cysts compared to larger cysts in 
wild type and mutant kidneys. At day 7, dilated tubules and cysts in mutants show a slightly lower 
PI compared to total wild type tubules. The proportion of mitotic cells in cysts is significantly 
higher than in cells of wild type kidneys at day 21 (mean 10.88 ± 4.08 versus mean 3.06 ± 0.85 p=0.03). 
*=p<0,05
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wild type and mutant kidneys (Figure 4A). In wild type and mutant mice, proliferation 
was highest in the early developmental stages, days 7 and 13. At day 21, the percentage of 
proliferating cells strongly decreased in wild type mice, but not as much as in the mutants 
(wild type 0.68 ± 0.48 versus mutant 9.73± 3.81, P=0.05) (Figure 3, G and H, and Figure 
4A). Furthermore, at day 21, cysts exhibited more proliferating cells than the nephrons in 
wild type kidneys (Figure 3F and Figure 4B). The PI, however, was not different between 
small and large cysts. We observed increased proliferation in some groups of cysts and 
dilated tubules, indicating that proliferation may occur in regional bursts rather than at 
random.
In general, Apoptosis was minimal, and it was comparable in wild type and mutant 
kidneys at days 7-21. Only at the ages of 3 and 4 weeks a few apoptotic cells were 
observed in the epithelium of large cysts, indicating that apoptosis may not be a major 
factor for early cystogenesis in this mouse model.
Collagen accumulation was analyzed by Sirius red staining. At early ages, no signs of 
collagen deposition were observed, but, at days 10 and 13, collagen started to accumulate 
around some cysts. The area of collagen deposition and the number of cysts surrounded 
by collagen deposition increased at days 21 and 28 (Figure 3, I through J).  Collagen is a 
target of SMAD2, a transcription factor involved in TGFß signaling. In cystic kidneys of 
several Pkd1-mutant mouse models transcript levels of SMAD2 target genes are 
up-regulated, e.g. matrix metalloproteinase-2 (Mmp-2), plasminogen activator inhibitor 1 
(Pai-1), collagen type 1 (ColI) and EDA-fibronectin (EDA-Fn).29 At early neonatal stages 
(days 1, 7, 13) expression of all these genes, which are involved in extracellular matrix 
synthesis and remodeling, is not significantly different compared to wild types 
(Figure 1D-I). At days 21 and 28, however, when renal development is completed, 
transcript levels decrease in wild types while in mutants expression levels are less 
decreased or are (strongly) increased. At all stages, transcript levels of Mmp14, encoding 
the activator of MMP2, show a very similar expression pattern as for Mmp2 (data not 
shown). For other genes involved in extracellular matrix remodeling, expression of the 
plasminogen activator inhibitor 1 (Pai-1) is strongly up-regulated in cystic kidneys, while 
expression of its target urokinase-type plasminogen activator (u-PA) is reduced 
(Figure 1G-H). Expression of another inhibitor in plasmin synthesis, alpha-2 antiplasmin 
(Serpin F1), is increased as well (Figure 1I).30 
Expression of genes encoding biomarkers Neutrophil gelatinase-associated lipocalin 
(Lcn2), sulfated glycoprotein-2 (Sgp-2) or clusterin and prostaglandin D2 synthase 
(Ptgds) are potential biomarkers to monitor disease progression.  For all three genes, 
expression levels increase with disease progression (Figure 1J-K). Also complement C3 
(C3), a potential biomarker and is an important player in the innate immunity response, is 
highly elevated in cystic kidneys (Figure 1L).
NKCC1 expression during Cyst Formation in C57Bl6/J-Pkd1nl/nl mice
Transepithelial Cl- secretion involves two steps: basolateral NKCC1 concentrates Cl- in 
the cell and apical CFTR channels release Cl- into the cyst lumen.31 It has been reported 
that NKCC1 localizes at the basolateral side of the cell.32 In C57Bl6/J-Pkd1nl/nl mice, a 
clear basolaterale staining was not always detected due to diffuse cytoplasmic staining. 
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The expression NKCC1 demonstrate a segment-dependent pattern. In proximal tubules 
and proximal cysts, NKCC1 was clearly expressed in the cytoplasm on days 1 through 7. 
On days 10 and 13, weak expression was observed in the medulla and in cysts 
originating from the collecting ducts and distal tubules. On days 21 and 28, the outer 
medulla exhibited slightly more staining for NKCC1 than in the inner medulla (Figure 3, 
K and L) (Table 2).
Tabel 2. NKCC1 expression in C57Bl6/J-Pkd1n/nl
Age NKCC1 expression in C57Bl6/J-Pkdnl/nl
Days 
1-3
• Cytoplasmic NKCC1 in (dilated) proximal tubules and proximal 
cysts.
• Wild type kidneys show cytoplasmic NKCC1 in proximal tubules. 
• Weak NKCC1 expression in (dilated) tubules in medulla.
• Wild type kidneys show weak cytoplasmic NKCC1 in the medulla. 
Day 
7
• Cytoplasmic NKCC1 in (dilated) proximal tubules and proximal 
cysts. 
• Wild type kidneys show cytoplasmic NKCC1 in proximal tubules.
• Weak NKCC1 expression in (dilated) tubules in medulla. 
• Wild type kidneys show weak cytoplasmic NKCC1 in the medulla.
Days 
10-13
• Cytoplasmic NKCC1 in proximal tubules of mutant kidneys. 
• Wild type kidneys show cytoplasmic NKCC1 in proximal tubules.
• Weak cytoplasmic NKCC1 expression in the medulla, in distal 
tubules, collecting ducts and in cysts in mutants. 
• Wild type kidneys show weak cytoplasmic NKCC1 in the medulla.
Days 
21 -28
• Cytoplasmic NKCC1 expression in proximal tubules of mutant 
kidneys. 
• Wild type kidneys show cytoplasmic NKCC1 in proximal tubules.
• Weak cytoplasmic NKCC1 expression in the medulla, in distal 
tubules, collecting ducts and in cysts in mutants. Only small cysts 
and tubules in the outer medulla show basolateral NKCC1 expres-
sion, like tubules of the same region in wild type kidney.
• The outer medulla exhibited slightly more staining for NKCC1 than 
in the inner medulla.
Discussion
The Pkd1nl/nl mouse model is an orthologous model for polycystic kidney disease. The 
severity of the phenotype varies among mice with a mixed genetic background.9 In this 
study, we found that, on a C57Bl6/J background, these mice present with a rapidly 
progressive phenotype and die between 3 and 4 weeks of age. All models homozygous 
for a Pkd1 inactivating allele present with severe cystic kidneys around E15, indicating 
that polycystin-1 is required for normal kidney development.10-13,16 The C57Bl6/J-Pkd1nl/nl 
mice, however, express low levels of Pkd1, are viable, and exhibit grossly normal kidney 
structure but with dilated proximal tubules at birth. 
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The first cysts develop from the fully mature proximal tubules and not from the comma or 
S-shaped bodies in the nephrogenic zone in the outer cortex. This is followed by a phase 
of distal tubule and collecting duct cyst formation and progressive enlargement leading 
to renal failure. In contrast to knock-out mice, C57Bl6/J-Pkd1nl/nl mice do not develop 
glomerular cysts, indicating that the low expression of Pkd1 is sufficient to maintain a 
normal glomerular structure, and the total loss of Pkd1 induces glomerular cysts 
during embryonic development.11,12,16,33 Those  glomerular cysts observed in Pkd1 knock-
out  mice were only observed for glomeruli located in the deep medulla zone, whereas 
superficial glomeruli located in the cortex among comma and S-shaped bodies were non-
cystic.33
Interestingly, in a recent study two pedigrees were described without family history of 
polycystic kidney disease, each containing two patients with in utero onset of PKD. The 
renal cystic phenotype was typical for ARPKD. Mutation analysis, however, did not 
reveal mutations in the PKHD1 gene, but revealed two hypomorphic PKD1 alleles.8 
Histologic analysis of renal tissue of an affected fetus obtained after abortion at 20 weeks 
pregnancy revealed that the majority of cysts (77%) were of proximal tubular origin. 
Thus, in both the mouse model as well as the patient carrying two hypomorphic PKD1 
alleles, the first cysts are formed in the proximal tubules.
The pattern of nephron segment-specific cyst formation during nephrogenesis could be a 
reflection of Pkd1 expression. The first cysts are formed in the proximal tubules, but, over 
time, cysts derived from the collecting ducts and distal tubular segments can be 
identified. In immature proximal tubules, Pkd1 expression is high and declines 
progressively in mature proximal tubules but starts to increase in the loop of Henle, distal 
tubules, and collecting ducts, a pattern that persists in adult kidneys.34,35 Also, in other 
models of ADPKD or ARPKD (e.g. cpk/cpk, BALB/c-bpk/bpk, TG737orpk, and kat2J 
mutant mice, and Han:SPRD and wpk rat models), this segment-specific pattern of cyst 
formation has been observed.36-44
Since Pkd1 and the tuberus sclerosis 2 (Tsc2) gene are located, tail-to-tail, only 63 
basepairs apart we analyzed Tsc2 gene expression.18 At all ages Tsc2 gene expression 
was lower. In mice with neonatally induced Pkd1 inactivation Tsc2 expression was also 
reduced at 28 days. However, in mice with Pkd1 inactivation at adult age, expression was 
not altered (data not shown), suggesting that the combination of developmental stage and 
Pkd1 inactivation affects gene expression.
A variety of studies indicate increased apoptosis and/or cell proliferation in the cystic 
kidneys of animal models and ADPKD patients.25-28 In C57Bl6/J-Pkd1nl/nl mice, the 
overall proliferation index in the renal epithelium at neonatal stages was not significantly 
higher compared to wild type mice, which is similar to what has been reported for young 
inducible Pkd1 deletion mice.33,45 Proliferation is much higher in the kidneys of 7- and 
13 day-old mice compared to 21 day-old mice, a phenomenon related to a developmental 
switch in kidney maturation.45 Comparing epithelial cell proliferation in cortex, cortico-
medullary region and medulla,  proliferation is at days 7 and 13 highest in the cortico-
medullary region, both in wild type and mutant kidneys. This is a major growth zone 
for medullary structures and the region from which the majority of cysts are derived in 
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C57Bl6/J-Pkd1nl/nl.46 This is in line with our previous report showing that knocking-out 
Pkd1 at postnatal day 4 results in massive cyst formation with the major involvement of 
the distal nephron, whereas gene disruption in adults (5.5 weeks and 3 to 5 months of age) 
results in cyst formation in all segments of the nephron.33,47 
A driving force for transepithelial fluid secretion is transepithelial Cl- secretion mediated 
by NKCC1 and CFTR.31 In general, the nephron-segment expression pattern of NKCC1 
in cystic kidneys is similar to the pattern observed in wild type kidneys, e.i. relatively 
strong expression was observed in proximal tubule derived cysts, but only weak 
expression in cysts derived from distal tubules and collecting ducts. In C57Bl6/J-
Pkd1nl/nl mice, the first cysts are formed in the proximal tubules. Accordingly, in this 
model, the strongest NKCC1 expression is observed in cysts at younger ages. In different 
inducible Pkd1 deletion mice, only weak expression of NKCC1 was observed in mice 
with cysts derived from the distal part of the nephron, while high expression was seen in 
a model with a large proportion of cysts being of proximal tubular origin (not shown). 
In C57Bl6/J-Pkd1nl/nl mice, the accumulation of collagen is relatively mild compared to 
human cystic kidneys, probably because these mice do not live long enough for the 
development of progressive fibrosis. Expression of SMAD2 targets (Mmp2, EDA-Fn, 
ColI and Pai-1) all show a developmental expression pattern, e.g. expression is 2 to 5 
times down-regulated in wild types at days 21 and 28, compared to days 1-13 (Figure 1 
D-H). This is in agreement with reduced expression of TGFß receptors in adult rats 
compared to developmental stages.48 In cystic kidneys, however, expression is 
moderate to strongly up-regulated compared to wild type littermates. Plasminogen 
activator inhibitor 1(Pai-1) is strongly up-regulated in cystic kidneys, while expression of 
its target urokinase-type plasminogen activator (uPA) is reduced. Expression of 
another inhibitor in plasmin synthesis, alpha-2 antiplasmin (SerpinF1), is increased as 
well (Figure 1I).  Plasmin is a serine protease with a broad substrate specificity including 
the extracellular matrix proteins laminin and fibronectin, either directly or indirectly via 
MMP’s.30 Although the role of the plasminogen activator system in PKD is not clear yet, 
these data suggest a role in extracellular matrix accumulation via reduced degradation of 
ECM components. 
Urinary biomarkers reflecting renal tubular damage or inflammation are getting 
increasing attention.49 We measured increased expression of transcripts encoding LCN2, 
sulfated glycoprotein-2 (or clusterin), prostaglandin D2 synthase and complement C3 in 
cystic kidneys (Figure 1J-L). These genes were selected because the encoded proteins are 
potential biomarkers and/or differential expression observed expression arrays. The latter 
three proteins were also measured in a proteomic analysis of cyst fluid.50 An association 
of urinary levels of LCN2 and renal volume has previously been reported for ADPKD49 
and elevated expression of sulfated glycoprotein-2 and complement C3 has previously 
been reported in renal cystic tissues.51
The observed early mortality is probably caused by rupture of dissecting aneurysms, 
which are found in large vessels like the aorta and mesenteric artery at the age of 3 
weeks in most C57Bl6/J-Pkd1nl/nl mice (8 out of 9),24 although renal failure cannot be 
entirely excluded because blood urea levels were moderately elevated in a few mice, 
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at 3 weeks (data not shown).  These manifestations may also occur more frequently or 
more severe in the patients with two hypomorphic alleles. On the other hand, in general 
patients with ADPKD show variation in disease progression, and although the factors that 
affect this diversity are not clear, modifying genes and environmental factors are probably 
involved.52 Other extra-renal manifestations that can also be (less frequently) found in 
ADPKD patients are cysts in liver and pancreas, but were not observed in these mice.9,17,53
There are phenotypic differences between ARPKD and ADPKD. Ductal plate 
malformations and congenital hepatic fibrosis are considered characteristic for ARPKD. 
As in C57Bl6/J-Pkd1nl/nl mice, also the patient with two hypomorphic Pkd1 alleles who 
died in utero with severe renal cystic disease, did not show these manifestations.8 Renal 
cysts, however, had a fusiform appearance as in ARPKD, probably because at the same 
time many epithelial cells become cysts, rather than a single cell or small group of cells 
as result of second hits. 
In conclusion, the renal cystic phenotype of C57Bl6/J-Pkd1nl/nl mice, seems to reflect the 
phenotype of patients with early onset PKD as result to two hypomorphic mutations. The 
first cysts are formed in the proximal tubules, but, over time, cysts derived from the 
collecting ducts and distal tubular segments can be identified.
Methods
Mice
The Pkd1nl/nl mice were generated as previously described in detail.9 A loxP-flanked neomycin selection cassette 
was inserted into intron 1 of Pkd1 by homologous recombination and a third loxP site was inserted into intron 
11. Chimeric offspring were backcrossed with C57Bl6/J mice for 12 generations, resulting in an almost 100% 
C57Bl6/J background. 
All experiments with mice were approved by the Animal Care and Use Committee of Leiden University and by 
the Commission for Biotechnology in Animals of the Dutch Ministry of Agriculture.
Immunostaining
Immunohistological analysis was performed on 24 Pkd1nl/nl and 22 wild type kidneys from mice of different ages 
(1, 3, 7, 10, 13, 21, and 28 days old). The kidneys were fixed in 4% phosphate buffered formalin, dehydrated in 
graded ethanol and xylene, and embedded in paraffin. Sequential sections of 4 µm were mounted onto 
superfrost-plus glass slides. After de-paraffinization, sections were stained using standard procedures.54 
Antigen-retrieval, at 100oC for 10 min in citric acid buffer (0.01 M, pH 6.0), was performed for Ki67 and 
caspase-3; and it was performed for NKCC1 in Tris:EDTA (10:1 mM). The antibody complexes were visualized 
using 0.04% diaminobenzidine-tetra-hydrochloride (DAB) with 0.5% CuSO4 or 0.7% NiCl2. Incubation of the 
NKCC1 antibody with a 50–fold excess of blocking peptide completely eliminated staining. For histological 
analysis kidney sections were stained with hematoxylin-eosin (HE) and Sirius red (collagen staining). Sirius 
Red stains collagen type I, II and III.55,56
Antibodies
The following primary antibodies were used: anti-caspase-3 (1:300; Cell Signaling, Leiden, the Netherlands), 
anti-Ki67 (1:3000; Novocastra, Valkenswaard, the Netherlands), anti-megalin (1:500; Pathology, Leiden, the 
Netherlands),19 anti-uromodulin/Tamm Horsfall (1:3000; CAPEL, Durham, NC), anti-aquaporin-2 (1:300; Cal-
biochem, Amsterdam, the Netherlands), anti-NKCC1 (1:100; Santa Cruz, Heidelberg, Germany). Secondary 
antibodies were rabbit envision/HRP (undiluted; Dako, Heverlee, Belgium) and rabbit-anti-goat Ig/HRP (1:100; 
Dako, Heverlee, Belgium).
mRNA Quantifications
Transcription levels were determined by Reverse Transcriptase Multiplex Ligation-dependent Probe 
Amplification (RT-MLPA). The reactions were performed as previously described.57 Briefly, 21 wild type and 
19 Pkd1nl/nl kidneys from mice of different ages (1, 7, 10, 13, 21, and 28 days old) were homogenized and total 
RNA isolated. From an aliquot of 200-300 ng total RNA, cDNA was synthesized. Two separate hybridization 
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reactions were performed with this cDNA. To each sample, MLPA probe mix and SALSA MLPA buffer were 
added (MRC-Holland, Amsterdam, the Netherlands), and the samples were incubated at 95°C  for 1 min 
followed by 60°C for 4 hours. We developed two Pkd1 probe sets: the 5’ Pkd1 probe set specifically identified 
the normal Pkd1 transcript and the 3’ Pkd1 probe set identified both mutant and normal Pkd1 transcripts. The 
sequences of probes and oligonucleotides are available upon request. The ligation of the annealed 
oligonucleotides was performed at 54°C for 10-15 min. The ligase enzyme was inactivated by heating at 98°C 
for 5 min, and the ligation products were amplified by PCR using SalsaTaq (Applied Biosystems, Nieuwekerk 
a/d Ijssel, the Netherlands). The amplified samples were mixed with Hi-Di Formamide containing 
GeneScan-500 ROX size standard (Applied Biosystems, Nieuwekerk a/d Ijsel, the Netherlands) heated for 5 
min at 95°C and run on a 3730 DNA analyzer (Applied Biosystems, Nieuwekerk a/d Ijsel, the Netherlands). 
Data were analyzed using GeneScan Analysis 3.5 and Microsoft Excel software. For situations in which off-
scale signals needed to be reduced, competitor oligonucleotides were applied. The expression of the 
housekeeping gene Hprt (hypoxanthine guanine phosphoribosyl transferase) served as references for gene 
expression. Peak ratios of the target gene and housekeeping gene were calculated, and results of the mutant and 
wild type kidneys were normalized to the mean of wild type kidneys at day 28, which was set to 1. The expres-
sion levels of the wild type and mutant mice of the same age were compared with an unpaired 2-tailed t-test. A 
p-value of <0.05 (2-tailed) was considered significant
Proliferation Index (PI)
The PI was calculated for 11 wild type and 12 mutant kidneys from mice of different ages (7, 13, and 21 days 
old) as previously described by counting the percentage of Ki-67-positive renal epithelial cells in four to ten 
randomly selected fields of a cross-section.33 Between 1000 and 3000 tubular epithelial nuclei of normal, 
dilated tubules and small cysts were counted per mouse. From large cysts, which were defined as being five 
times larger than normal tubules, between 300 and 1000 nuclei were counted per mouse. Only clearly 
definable heavy or granular nuclear staining was identified as positive. The PI values of the wild type and mutant 
mice were compared with an independent sample 2-tailed t-test. The PI values of (dilated) tubules and large 
cysts within one mouse were compared by a paired 2-tailed t-test. A p-value of <0.05 (2-tailed) was considered 
significant.
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Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited renal 
disease characterized by many fluid-filled cysts and interstitial fibrosis in the kidneys 
leading to chronic renal failure. During cystogenesis the renal tubules undergo extensive 
structural alterations that are accompanied by altered cellular signaling, directly and/or 
indirectly regulated by the PKD1 and PKD2 proteins. 
Since transforming growth factor b (TGF)β signaling modulates cell proliferation, 
differentiation, apoptosis, adhesion, and migration of various cell types, we studied the 
activation of this signaling pathway in Pkd1-mutant mouse models at different stages of 
the disease.  Therefore, we analyzed expression the TGFb/Smad signaling pathway and 
its target genes in different Pkd1 mutant mouse models in various stages of polycystic 
disease. Nuclear accumulation of P-Smad2 in cyst lining epithelial cells was not observed 
in the initiation phase but was observed at mild and more advanced stages of PKD. This 
coincides with mild fibrosis and increased mRNA-levels of TGFβ target genes, like 
fibronectin, collagen type I, plasminogen activator inhibitor 1 and matrix metallo-
proteinase-2. At this stage many interstitial fibroblasts were found around cysts, which 
also showed nuclear localization for P-Smad2.  However, bone morphogenetic protein 
(BMP) signaling, which can antagonize TGFβ signaling, is not affected since nuclear 
expression of P-Smad1/5/8 and expression of the BMP target gene, inhibitor of DNA 
binding/differential-1 (Id-1) is not altered compared to wild type controls. Also human 
kidneys with progressive ADPKD showed increased nuclear localization of P-Smad2 
while in general expression of P-Smad1/5/8 was weak. These results exclude TGFβ 
signaling at the initiation of cystogenesis, but indicate an important role during cyst 
progression and in fibrogenesis of progressive ADPKD.   
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
inherited diseases. In 85% of the patients, the gene responsible for the disease is PKD1, 
which encodes polycystin-1, whereas in 15% of patients the mutation is in the PKD2 
gene, which encodes polycystin-2. The proteins are involved in a variety of functions like 
mechano-sensing, cellular signaling and cell-cell/cell-matrix interactions.1-4 The main 
features of the disease are the formation of many fluid-filled cysts in the kidneys as well 
as interstitial fibrosis leading to progressive loss of normal renal tissue and resulting in 
chronic renal failure.5 Cystogenesis is characterized by proliferation of the epithelium, 
excessive secretion of solute and fluid into the cysts and remodeling of the extracellular 
matrix, processes that are also regulated by growth factors, hormones, and cytokines of 
the kidneys.1 
The transforming growth factor b (TGFb) super family members are multifunctional 
cytokines that modulate many of these process like proliferation, differentiation, 
apoptosis, adhesion, cell migration and these cytokines are believed to play a crucial 
role in fibrotic deposition.6 Indeed, several lines of evidence suggest that altered TGFb 
signaling is implicated in PKD.  Mice with overexpression of the BMPs receptor activin 
receptor-like kinase (ALK)-3 as well as Bmp-7 knock-out mice develop polycystic 
kidneys.7,8 Also BMP-7 treatment of the jck mouse, retarded cyst formation.9 In addition, 
increased levels of TGFb transcripts are found in kidneys of  the pcy model and reduced 
expression of P-Smad1 has been reported for the cpk/cpk mouse.10,11 However, none of 
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these PKD models have a targeted mutation in the Pkd1 or 2 genes. In addition, several 
studies performed on end-stage ADPKD-kidneys suggested involvement of TGFb 
signaling in polycystic kidney disease. 12-14 In the current study, we analyzed the 
activation of the TGFb/Smad signaling pathway at different stages of polycystic disease 
in different Pkd1 mutant mouse models and in human ADPKD-tissues.15,16 
Results 
In this study we analyzed TGFb and BMP signaling in different Pkd1 mouse models 
at different stages of disease. These cytokines bind to a pair of serine/threonine kinase 
transmembrane receptors that mediate the phosphorylation of receptor-regulated Smads 
(R-Smads). R-Smad2 and 3 are activated by TGFβ, and R-Smads1, 5 and 8 act down-
stream of BMP. Phosphotylated R-Smads can form a heteromeric complex with Smad4 
and these complexes accumulate in the nucleus where they act as transcription factors.6 
TGF-b and P-Smad2 Expression at Different Stages of PKD in C57Bl6/J-Pkd1nl/nl 
Kidneys
C57Bl6/J-Pkd1nl/nl mice have reduced levels of Pkd1 gene expression and present a 
rapidly progressive phenotype. The first dilated tubules can be seen at day 1 and are of 
proximal tubular origin (megalin positive), while at days 10 and 13 the majority of cysts 
are derived from the collecting ducts (aquaporine-2 positive). At days 21 and 28, most 
cysts stain positive for Tamm Horsfall protein (loop of Henle and distal convoluted 
tubule) or aquaporine-2 (collecting duct) (Hassane et al. unpublished). 
We analyzed TGFb (active and non-active protein) expression in the kidneys of 
C57Bl6/J-Pkd1nl/nl mice by immunohistochemistry. In wild type renal tubular epithelium, 
TGFb was localized at the basolateral membrane and in the cytoplasm of all segments 
(Figure 1A insert) (Table 1). In cystic kidneys, the majority of the cysts was positive for 
TGFb, which was expressed in the cytoplasm (Figure 1B). The expression level, 
however, seemed not to be increased compared to wild types. 
The downstream intracellular target of TGFb, P-Smad2, exhibits a weak expression in 
wild type kidneys at all ages (Figure 1C). In mutant kidneys, P-Smad2 showed strong 
nuclear staining in the few relatively large proximal cysts present at day 7 and in the 
majority of the medullary derived cysts at days 21 and 28 (Figure 1D), suggesting 
activation of TGFb signaling in cystic epithelium. At days 21 and 28 many interstitial 
cells were found around cysts, these cells also showed nuclear localization for P-Smad2 
(Figure 1D insert) and very weak cytoplasmic staining for TGFb. To quantify these 
results we performed a western blot for P-Smad2 at day 21 on C57Bl6/J-Pkd1nl/nl mice 
and controls. Indeed, P-Smad2 levels were significantly increased in the mutant kidneys 
(6.3 times, p= 0.0002) (Figure 1Q and R).
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Figure1. TGFb signaling in Pkd1 mutant mice and ADPKD kidneys.
Antibody complexes in tissues are visualized using 0.04% DAB-0.5% CuSO4 (brown staining). 
Bar = 100mm
(A) Basolateral and cytoplasmic TGFb localization in wild type kidneys at day 21. (insert A) 
Basolateral TGFb expression in 21-days-old wild type kidney. (B) Cytoplasmic TGFb 
expression in cyst lining cells and weak expression in interstitial cells in C57Bl6/J-Pkd1nl/nl at day 
21. (C) Weak cytoplasmic P-Smad2 expression in cortex in wild type kidneys at day 21. (D) Strong 
nuclear expression of P-Smad2 in cyst lining cells, and interstitial cells (insert) in C57Bl6/J-
Pkd1nl/nl at day 21. (E) Weak P-Smad2 expression in medulla of 1 month old wild type kidney. (F) 
Strong nuclear localization of P-Smad2 (arrow) in medullary cysts and in surrounding interstitial 
cells of the PN4 mouse model, 30 days after Pkd1 gene disruption. (G) Weak P-Smad1/5/8 expres-
sion in wild type kidney at the age of 1 month. (H) Weak P-Smad1/5/8 expression in cysts of PN4 
mouse, 30 days after Pkd1 gene disruption. (I) Nuclear and cytoplasmic P-Smad2 in tubules of 
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Table 1. TGFb and BMP signaling in C57Bl6/J-Pkd1nl/nl mice.
Age TGFb, P-Smad2 and P-Smad1/5/8 expression
Days 
1-3
• TGFb cytoplasmic in all (dilated) tubules. 
• P-Smad2, weak cytoplasmic and nuclear in mature proximal (dilated) 
tubules, and relatively weak in tubules of the rest of the kidneys, like in 
wild type kidneys.
• P-Smad1/5/8, variable levels of nuclear expression in all (dilated) tubules 
in the kidneys, while cytoplasmic expression is weak. Same pattern found 
in wild type kidneys
Day 7 • TGFb strong basolateral and/or cytoplasmic expression in distal tubules 
and collecting ducts, as in wild type kidneys. Basolateral and cytoplasmic 
in proximal cysts. 
• Increased nuclear P-Smad2 in proximal cysts and relatively weak nuclear 
localization in all dilated tubules in medulla.
• P-Smad2 in tubules is comparable to days 1-3, as in wild type kidneys. 
• Increased nuclear P-Smad1/5/8 in proximal cysts.




• TGFb basolateral and/or cytoplasmic in cysts. 
• Increased nuclear P-Smad2 in few cells of some cysts.
• P-Smad2, in cortex stronger cytoplasmic expression than in medulla, as 
in wild type kidneys.  
• P-Smad1/5/8 in tubules is comparable to days 1-7, as in wild type 
kidneys. In cysts, P-Smad1/5/8 is very weak in the nucleus and cytoplasm.
Days
21-28
• TGFb basolateral and/or cytoplasmic in cysts. 
• Increased nuclear P-Smad2 in cystic epithelium and in interstitial cells 
around cysts.
• P-Smad1/5/8 in cysts at days 21 and 28 is very weak nuclear and 
cytoplasmic. Expression in tubules at day 21 is comparable to days 1-13, 
as in wild type. At day 28, nuclear and cytoplasmic expression is weak 
although the tubules in cortex showed a slightly stronger nuclear P-
Smad1/5/8 expression compared to medulla.
cortex of 5 months old wild type kidney. (J) Nuclear and cytoplasmic P-Smad2 in proximal cysts of 
the PN40 mouse model, 4 months after Pkd1 deletion. (K) Nuclear and cytoplasmic P-Smad1/5/8 
in cortex of 5 months old wild type kidney.  (L) Decreased nuclear P-Smad1/5/8 localization (ar-
row) in proximal cysts of PN40 mouse model, 4 months after Pkd1 deletion. (M) In human controls 
kidneys, very weak cytoplasmic and nuclear P-Smad2 in tubules. (N) In human ADPKD kidneys, 
strong nuclear P-Smad2 expression in cyst lining cells (arrow) and interstitial cells. (O) In human 
control kidneys, weak P-Smad1/5/8 expression in tubules. (P) In human ADPKD kidneys, weak 
P-Smad1/5/8 expression in cysts. (Q) P-Smad2 western blot with a-tubulin as loading control. 1= 
MCF10 cells not stimulated with TGF-b negative control. 2= MCF10 cells stimulated with TGF-b, 
positive control. 3-5= C57Bl6/J-Pkd1nl/nl at day 21. 6-8= wild type at day 21. (R) Ratio P-Smad2/a-
tubulin in C57Bl6/J-Pkd1nl/nl and wild type kidneys. P-Smad2 is increased in C57Bl6/J-Pkd1nl/nl. 
Mean P-Smad2/a-tubulin ratio of the mutant kidneys was normalized to the mean ratio in wild type 
kidneys which has been set to 1. * = p<0.05
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P-Smad1/5/8 Signaling at Different Stages of PKD in C57Bl6/J-Pkd1nl/nl Kidneys
P-Smad1/5/8 acts downstream of BMPs. Antibodies against P-Smad1/5/8 showed 
variable levels of expression in the nucleus in all tubular segments in wild type kidneys 
(Table 1). Only at day 28, the cortex showed a stronger nuclear P-Smad1/5/8 expression 
compared to medulla. In C57Bl6/J-Pkd1nl/nl mice the early proximal tubular cysts showed 
a relatively strong nuclear localization for P-Smad1/5/8 but the medullary derived cysts 
at days 21 and 28, exhibited a very weak nuclear localization (data not shown). These 
results indicate that there is no strong activation of P-Smad1/5/8 signaling during cyst 
formation and cyst growth.
P-Smad2 and P-Smad1/5/8 Expression at different stages in kidneys of young and adult 
inducible Pkd1-deletion mice
To further analyze TGFb signaling during cyst formation we analyzed renal tissues from 
a conditional and inducible Pkd1-deletion mouse model.16  In this model Pkd1 gene 
deletion is induced by tamoxifen administration. Timing of Pkd1 disruption affects the 
phenotype. Tamoxifen administration at day 4 (PN4) induces 5% Pkd1 gene disruption, 
as measured by extension MLPA (eMLPA)17. This results in a limited number of fast 
progressing cysts within one month. These cysts originate mainly from distal tubules and 
to less extent from collecting ducts. These cysts as well as the interstitial cells showed 
increased nuclear localization of P-Smad2 (Figure 1E and F), while levels and expression 
pattern of P-Smad1/5/8 were comparable to wild type kidneys (Figure 1G and H) (Table 
2). 
Table2. TGFb and BMP signaling in Pkd1-deletion mice.
Mouse P-Smad1/5/8 and P-Smad2 expression
PN4+
1 month
• Increased nuclear P-Smad2 in distal cysts and interstitial cells. 
• P-Smad1/5/8, weak nuclear as well as cytoplasmic expression in 
tubules. Same pattern as in wild type kidneys.
• P-Smad1/5/8 very weak cytoplasmic in distal cysts. 
PN40+
4 months
• P-Smad2 nuclear and cytoplasmic expression in cysts in cortex. 
Same pattern as in cortex of wild type kidneys.
• P-Smad2 variable levels of nuclear expression in outer medulla. 
Strong nuclear expression in inner medulla. Same pattern as in 
wild type kidneys
• Decreased nuclear P-Smad1/5/8 in most proximal dilated tubules 
and cysts.  A few proximal cysts showed rather strong nuclear 
expression.
• P-Smad1/5/8 very weak cytoplasmic and nuclear expression in 
medulla. Same pattern as in wild type kidneys.
Deleting Pkd1 at day 40 (PN40) results in a cystic phenotype showing many dilated 
tubules in the cortex and medulla after 3 months and proximal cysts after 4 months. 
Nuclear localization of P-Smad2 was detected in cysts and dilatations of the outer cortex 
and less in the inner cortex at 3 and 4 months after gene disruption. The expression level 
and pattern were comparable to wild type kidneys (Figure 1I and J) (Table2). On the other 
hand, the expression of P-Smad1/5/8, was almost absent in the nucleus of most proximal 
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cysts and dilatations, while in wild type kidneys weak nuclear and cytoplasmic signal 
was observed, suggesting increased Smad2-mediated gene expression in cystic epithe-
lium (Figure 1K and L). At the early stages, when no dilatations or cysts were observed, 
P-Smad2 and P-Smad1/5/8 expression levels and patterns were comparable to wild types 
(not shown).
P-Smad2 and P-Smad1/5/8 in ADPKD Patients
The kidneys of 4 healthy individuals and 9 end stage ADPKD-patients were analyzed as 
well. In general, expression of P-Smad2 and of P-Smad1/5/8 was weak in control kidneys 
(Figure 1M and O), except for some tubules that showed strong nuclear and cytoplasmic 
signals for both groups of Smads. In patients, strong nuclear staining for P-Smad2 was 
frequently seen in groups of cysts. In these areas cysts as well as the surrounding fibrotic 
tissue stained positive for P-Smad2 (Figure 1N). For P-Smad1/5/8 the majority of the 
cysts showed only weak nuclear and cytoplasmic staining (Figure 1P). Only a few cysts 
were positive for P-Smad1/5/8. These results are in line with expression pattern we found 
in our mouse models and support the notion that Smad2-signaling is increased in more 
advanced cystic kidneys, while Smad1/5/8-regulated signaling is hardly activated. 
Expression of Target Genes During Early and Progressive Stages of PKD. 
To determine the expression of  TGFb target genes, transcript levels of  matrix metallo-
proteinase-2 (MMP-2), Plasminogen activator inhibitor 1 (PAI-1), collagen type 1 and 
EDA-fibronectin were measured in 21-days-old C57Bl6/J-Pkd1nl/nl kidneys.25-29 Also 
expression of MMP-14, an acitvator of MMP-2 was analyzed.30 Expression of all these 
genes was significantly increased in C57Bl6/J-Pkd1nl/nl kidneys (Figure 2A). To confirm 
elevated MMP-2 expression at the protein level, we did immunohistochemical analyses 
on C57Bl6/J-Pkd1nl/nl kidneys at different ages. In wild type kidneys MMP-2 expression 
was almost absent (Figure 3A). In mutant kidneys, however, MMP-2 expression
increased in cystic epithelium as cyst formation progresses (Figure 3B, arrow), starting at 
day 7 in proximal cysts. These cysts also showed increased nuclear P-Smad2 expression.
Furthermore, we measured expression of TGFb target genes in Pkd1 deletion mouse 
models (PN4 and PN40) at initiation and more advanced stages of PKD. In both models 
expression was significantly increased only at more advanced stages of the disease but 
not at the earliest time points (Figure 2B and C). In addition, the levels of one BMP target 
gene, Inhibitor of DNA binding/differential-1 (Id-1),31 was measured as well. For this 
gene, transcript levels were comparable to wild type mice at early and more advanced 
stages of the different models (Figure 2A and B). These data are in line with the immuno-
histochemical data that indicate activation of TGFb signaling, but not BMP signaling, at 
late stage PKD.
Fibrosis in Pkd1 Mutant Mouse Models 
Renal fibrosis is accompanied by an increase in interstitial fibroblasts and by extra-
cellular matrix deposition, e.g. collagen.32 Furthermore, TGFb can transform 
fibroblasts to myofibroblasts, which can be identified as interstitial cells expressing 
a-mooth muscle actin.33 Therefore we analyzed the expression of a-smooth muscle actin 
(a-SMA), collagen (sirius red) and the fibroblast marker Fibroblast Specific Protein-1 
(FSP-1).34 At days 1 through 7, no fibrosis was detected in C57Bl6/J-Pkd1nl/nl kidneys. 
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At days 10 and 13, a-SMA positive myofibroblasts were found around most cysts at the 
cortico-medullary region, while collagen started to accumulate around a few of the cysts. 
The amount of fibrotic tissue and the number of cysts surrounded by a-SMA positive 
cells and collagen increased at days 21 and 28 (Figure 3C-F). The tissue area occupied by 
a-SMA positive cells was quantified at day 28, revealing a significant increase of a-SMA 
in cortex and medulla (cortex 2.39 ± 0.77 vs. 16.73 ± 3.47 p=0.005; medulla 2.07 ± 1.47 
vs. 23.05 ± 4.28 p=0.04) (Figure 4A and B). Collagen deposition was also significantly 
increased (cortex 7.48 ± 5.09 vs. 29.57 ± 0.19 p=0.004) (Figure 4E and F). 
The inducible Pkd1-deletion mouse model, PN4+1m, showed a similar result for a-SMA 
as C57Bl6/J-Pkd1nl/nl, in cortex and medulla (cortex 2.39 ± 0.77 vs. 9.24 ± 1.89, p=0.01; 
medulla 2.07 ± 1.47 vs. 18.76 ± 3.35 p=0.004) (Figure 3G and 4A and B). Also collagen 
deposition was significantly increased in medulla (medulla 17.37 ± 8.38 vs. 41.91 ± 1.80 
p=0.02) (Figure 4E and F). The inducible Pkd1-deletion mice PN40+4m, showed a thin 
layer of a-SMA positive myofibroblasts around some cysts in cortex (Figure 3H), while 
the outer medulla with many dilated tubules showed an increased number of a-SMA 
positive cells (Figure 3I and J). 
Figure 2. Expression levels of BMP 
and TGFb target genes.
(A) Transcript levels of Id-1, a BMP 
target gene, and 4 TGFb targets genes, 
EDA-fibronectin (FN-EDA), PAI-1, 
MMP-2, and collagen type I (ColI), as 
well as levels of MMP-14, an activa-
tor of MMP-2, were determined by RT-
MLPA in 21-days-old C57Bl6/J-
Pkd1nl/nl and wild type kidneys. For 
each gene, transcript levels of the mu-
tant kidneys were normalized to the 
mean ratio of the same gene in wild 
type kidneys, which has been set to 1. 
In mutant kidneys expression of the 
TGF-b target genes is significantly el-
evated while expression of BMP target 
Id-1 is comparable to wild type kid-
neys. (B) TGFb and BMP target genes 
in Pkd1 deletion mouse PN40. The 
expression of TGFb target genes starts 
to increase 3 months after deletion of 
the Pkd1 gene and are significantly in-
creased after 4 months. Id-1 expression 
is not significantly altered at any time 
point. (C) Pkd1-deletion mouse PN4. The expression of TGFb target genes is not increased 14 
days after Pkd1 disruption, however, after 30 days TGFb target genes are increased. * = p<0.05
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Both, in cortex and medullar a-SMA expression was significantly increased in mutants 
compared to wild types (cortex 1.64 ± 0.22 vs. 7.73 ± 1.73 p=0.04; medulla 3.36 ± 
2.20 vs. 31.14 ± 0.68 p=0.03) (Figure 4A and B). Collagen deposition was significantly 
increased in medulla of PN40+4m mice (medulla 1.84 ± 0.24 vs. 4.19 ± 0.59 p=0.035) 
(Figure 4E and F). 
Figure 3. Fibrosis in Pkd1 mutant kidneys.
(A-B) staining MMP-2 (black staining) (C-D; G-J) staining for a-SMA (pink staining)(E-F) stain-
ing for sirius red (red staining) (K-L) staining for FSP-1 (brown staining). C&D and G-L are coun-
terstained with hematoxylin. (A) Virtually no MMP-2 expression is present in wild type kidneys at 
day 21. (B) Increased MMP-2 in cyst-lining cells (arrows) in C57Bl6/J-Pkd1nl/nl at day 21. (C) In 
cortex of 1 month old wild type kidneys only blood vessels show a-SMA positive cells (*=blood 
vessel).  (D) a-SMA positive cells particularly around cysts (arrow in insert) and dilated tubules in 
cortex of 1 month old C57Bl6/J-Pkd1nl/nl kidney. (E) Collagen deposition, visualized by Sirius red 
staining, in wild type kidney at day 21. (F) Collagen deposition is increased, particularly around 
cysts, in cystic kidneys of C57Bl6/J-Pkd1nl/nl mice, shown at day 21. (G)a-SMA positive cells in 
cortex of PN4 Pkd1-deletion mouse kidney at one month after gene disruption. Cyst lining cells 
are positive (arrow in insert) as well as interstitial cells surrounding cysts and tubules. (H) a-SMA 
positive interstitial cells in the cortex of PN40 Pkd1-deletion mouse kidney (arrow in insert), 4 
months after gene disruption. (I) In medulla of 1 month old wild type kidneys only blood capillar-
ies show a-SMA positive cells. (J) Many a-SMA positive interstitial cells in the medulla of PN40 
Pkd1-deletion mouse kidney, 4 months after gene disruption. (K) A few FSP-1 positive cells in 1 
month old wild type kidney. (L) Low number of FSP-1 positive cells in 1 month old C57Bl6/J-
Pkd1nl/nl kidney. A few flat cystic epithelial cells showed FSP-1 (arrow). Bar = 100mm
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Figure 4. a-SMA, FSP-1 and collagen expression in Pkd1 mutant kidneys.
Grey bars = 1 month old,  black bars = 5 months old.
(A-B) a-SMA in cortex and medulla of C57Bl6/J-Pkd1nl/nl and PN4+1m compared to wild type 
1 month (wt 1m), and PN40+4m compared to wild type 5 months (wt 5m). Significant increase 
of a-SMA in cortex and medulla in all mice. (C57Bl6/J-Pkd1nl/nl: cortex 2.4 ± 0.77 vs. 16.7 ± 
3.5, p=0.005; medulla 2.1 ± 1.5 vs. 23.1 ± 4.3, p= 0.04) (PN4+1m: cortex 2.4 ± 0.77 vs. 9.2 ± 
1.9, p=0.01; medulla 2.1 ± 1.5 vs. 18.8 ± 3.3, p=0.004) (PN40+4m: cortex 1.6 ± 0.2 vs. 7.7 ± 1.7 
p=0.04; medulla 3.4 ± 2.2 vs. 31.1 ± 0.7 p=0.03). *= p<0.05
(C-D) FSP-1 in cortex and medulla of C57Bl6/J-Pkd1nl/nl and PN4+1m compared to wild type 1 
month (wt 1m), and PN40+4m compared to wild type 5 months (wt 5m).
FSP-1 was significantly increased in cortex of C57Bl6/J-Pkd1nl/nl (C57Bl6/J-Pkd1nl/nl: cortex 2.33 ± 
1.03 vs. 5.05 ± 0.07 p=0.044). *= p<0.05
(E-F) collagen in cortex and medulla of C57Bl6/J-Pkd1nl/nl and PN4+1m compared to wild type 1 
month (wt 1m), and PN40+4m compared to wild type 5 months (wt 5m). Collagen deposition was 
significantly increased in all three models (C57Bl6/J-Pkd1nl/nl: cortex 7.48 ± 5.09 vs. 29.57 ± 0.19 
p=0.004) (PN4+1m: medulla 17.37 ± 8.38 vs. 41.91 ± 1.80 p=0.02) (PN40+4m: medulla 1.84 ± 
0.24 vs. 4.19 ± 0.59 p=0.035) *= p<0.05
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Expression of FSP-1 was significantly increased only in cortex of C57Bl6/J-Pkd1nl/nl mice 
(cortex 2.33 ± 1.03 vs. 5.05 ± 0.07 p=0.044). (Figure 3K and L and 4C and D). In general 
we see in all Pkd1 mutants, that most α-SMA positive fibroblasts were found as a second 
layer around the cystic epithelial cells (Figure 3D insert). The majority of cysts is 
surrounded by a-SMA positive cells, while only now end then a FSP-1 positive cell 
could be seen in the interstitium around cysts. In addition, a few flat cystic epithelial 
cells showed FSP-1 or a-SMA expression, suggesting that if epithelial-to-mesenchymal-
transition (EMT)  contributes to PKD and fibrosis, it is only to a very low extent (Figure 
3G and L). These flat FSP-1 or a-SMA positive cyst lining epithelial cells were more 
pronounced in the PN4 and less in the PN40 inducible mice and C57Bl6/J-Pkd1nl/nl mice.
Discussion 
Cystogenesis is characterized by epithelial cell proliferation, excessive secretion of solute 
and fluid into the cysts lumen and accumulation of matrix proteins in the renal 
interstitium, resulting into loss of functional renal tissue and interstitial fibrosis. TGFb is 
the major fibrogenic cytokine that has been studied in detail in renal interstitial diseases.35 
In this study, we show that TGFb signaling is not increased in the initial stage of cyst 
formation, but is increased during cyst expansion in more advanced stages of PKD in 
Pkd1 mutant mouse models and in ADPKD patient kidneys, which are characterized by 
progressive cysts formation and fibrosis. Increased nuclear localization of P-Smad2 
confirms activation of the TGFb signaling pathway and is consistent with the elevated 
mRNA levels of TGFb target genes, like EDA-fibronectin, collagen type I, PAI-1 and 
MMP-2, at later stages in the mouse models. These data are in line with studies on 
expression profiling of end-stage ADPKD kidneys and kidneys of Han:SPRD-Cy/+ rats, 
revealing upregulation of genes involved in extracellular matrix synthesis, EMT and 
fibrosis.13,36 Furthermore, expression of TGFb and TGFb regulated genes is low in young 
Han:SPRD-cy/+ rats but increases with progression of the disorder.37 In our Pkd1 mouse 
models, cytoplasmic TGFb expression as well as nuclear localization of P-Smad2 were 
detected in cystic epithelial cells as well as in interstitial cells suggesting that both cell 
types synthesize and respond to TGFb. Indeed, both interstitial cells as well as epithelial 
cells are sources of increased TGFb production and are major sites of matrix protein 
overproduction.38-42 
During epithelial-to-mesenchymal transition (EMT) epithelial characteristics are lost and 
a mesenchymal phenotype is acquired.43 The Pkd1 mutant mice sometimes showed flat 
cyst lining cells that were positive for FSP-1 or a-SMA. This phenomenon was more 
obvious in PN4 induced mice then in the other models. Differences in the stage of 
progressiveness of PKD, the developmental stage of the kidneys at the moment of 
gene-disruption and/or the nephron-segment from which cysts are derived (distal tubules 
in PN4) may play a role in this process. Overall, the proportion of FSP-1 or a-SMA 
positive epithelial cells is small. Furthermore, only incidentally single cells seemed to 
disconnect from the neighboring cells towards lumen or matrix. These data suggest that if 
EMT contributes to PKD and fibrosis, this is only to a very low extent. 
In the Pkd1 mutant mouse models presented here we observed relatively mild fibrosis 
with minor accumulation of collagen compared to human cystic kidneys. In these models, 
cyst formation progresses relatively fast and kidney failure occurs before the 
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development of progressive fibrosis. Similar to these mice, mild fibrosis was found in 
wpk and homozygous Han:SPRD-cy/cy rats and jcpk mice, which also show a rapidly 
progressive cyst formation.44-46 On the other hand, slowly progressive forms of PKD, such 
as heterozygous Han:SPRD-cy/+ rats, and pcy models and human ADPKD,
develop severe renal fibrosis.46-47 
Interstitial fibrosis is not only caused by increased matrix synthesis, but inadequate 
matrix degradation also contributes to the fibrogenic process.32 TGFb is involved in the 
regulation of both processes as it activates expression of matrix molecules (e.g. collagen 
I and EDA-fibronectin) and inhibitors of matrix degrading enzymes, thereby resulting in 
matrix accumulation. PAI-1, a negative regulator of MMP`s, is elevated in several acute 
and chronic renal disease.48-49 Upregulation of PAI-1 promoter activity by TGFb 
signaling is believed to be a major mechanism through which TGFb downregulates ECM 
degradation.50 Indeed, PAI-1 transcript levels were approximately 8-10 times increased 
in advanced stages in the Pkd1 mutant mice.  Levels of another Smad2 target involved in 
matrix remodeling, MMP-2 and its activator MMP-14, are 3 to 4 times increased in Pkd1 
mutant mice, suggesting a complex regulation of matrix remodeling with an imbalance 
towards accumulation of matrix proteins. 
The importance of BMP-7 for renal fibrosis was shown by several studies demonstrat-
ing that administration of BMP-7 reduces fibrotic tissues in various animal models of 
renal failure, by antagonizing TGFb.51-54 In C57Bl6/J-Pkd1nl/nl and young induced Pkd1 
deletion mice (PN4), P-Smad1/5/8 is hardly expressed in cysts and its expression is a 
reflection of the expression pattern found in wild type kidneys. This was accompanied by 
increased P-Smad2 activation in the same cysts in these mouse models. However at older 
ages in adult induced Pkd1-deletion mice (PN40), in the majority of cysts P-Smad1/5/8 
is excluded from nuclei of proximal cysts compared to the wild type kidneys, while P-
Smad2 remained localized in the nuclear compartment. This imbalance towards increased 
TGFb signaling observed in all three mouse models provides a rationale to test TGFb 
antagonists in PKD, at mild to advanced stages of PKD.
In conclusion, TGFb signaling is strongly increased at more advanced stages of 
polycystic kidney disease but is hardly altered at the early stage of the disease, suggesting 
that the TGFb signaling pathway is probably not implicated in initial steps of cyst 
formation.  Elevated TGFb signaling overlaps with and stimulates expression of matrix 
remodeling proteins, which are characteristic for fibrosis. These results suggest that 




The C57Bl6/J-Pkd1nl/nl mice were generated as previously described in detail.15 Offspring were backcrossed with 
C57Bl6/J mice for 12 generations, resulting in an almost 100% C57Bl6/J background. We analyzed C57Bl6/J-
Pkd1nl/nl at different ages (days 1, 3, 7, 10, 13, 21, and 28). The inducible Pkd1-deletion mice 
(tam-KspCad-CreERT2;Pkd1del2-11/lox2-11) and tamoxifen treatment have been described previously.16 Adult mice, 
were treated with 5 mg tamoxifen, at post-natal day 40 (PN40), for three consecutive days, and sacrificed 14 
days and 1, 2, 3, and 4 months later (PN40+14d, PN40+1m, etc). Young inducible mice received tamoxifen 
via breast-feeding from the mother starting at post-natal day 4 (PN4). These mice were sacrificed 13 days 
(PN4+13d) and one month (PN4+1m) later. Somatic Pkd1 gene disruption was confirmed by extension 
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Multiplex Ligation-dependent Probe Amplification (eMLPA) described previously.17 
All experiments with mice were approved by the Animal Care and Use Committee of Leiden University and by 
the Commission for Biotechnology in Animals of the Dutch Ministry of Agriculture.
Human Tissue Samples of Normal and Cystic Kidneys
Renal tissues from ADPKD patients with chronic renal failure and control renal tissues were fixed in 4% 
formalin and embedded in paraffin. Control tissues were isolated from donor kidneys intended for 
transplantation, but not suitable due to technical reasons. In total 4 control samples and 9 ADPKD cystic tissue 
samples of patients (8 with known mutations in or positive linkage to PKD1) were analyzed. 
All human tissue samples were analyzed following procedures approved by the ethical committee (institutional 
review board) of the Leiden University Medical Center.
Antibodies
The following primary antibodies were used: P-Smad1/5/8 and P-Smad2 (1:500; rabbit polyclonal 
antibodies),18-20 Fibroblast Specific Protein-1 (FSP-1, A5114; 1:800; rabbit polyclonal antibody; Dako, Hever-
lee, Belgium), matrix metalloproteinase-2 (MMP-2; mouse anti-human MMP-2 monoclonal antibody (Ab4), 
1:4, clone 75-7F7; Calbiochem, Amsterdam, the Netherlands), α-smooth muscle actin (a-SMA/AF (1A4) 
A5691; 1:100; mouse monoclonal antibody; Sigma, Zwijndrecht, the Netherlands), total TGFb 1 and 2  (active 
and inactive) sc-146; 1:1600; rabbit polyclonal antibody, Santa Cruz, Heidelberg, Germany. Of note: variations 
in between batches were observed). Secondary antibodies:  mouse envision/HRP (not diluted; Dako, Heverlee, 
Belgium), rabbit-anti-goat Ig/HRP (1:100; Dako, Heverlee, Belgium). 
 
Immunohistochemistry
Immunohistological analysis was performed on 24 C57Bl6/J-Pkd1nl/nl and 22 wild type kidneys of different 
ages. In addition, we analyzed kidneys of inducible Pkd1-deletion mice with Pkd1 gene disruption at post-natal 
day 4 (PN4) or post-natal day 40 (PN40). We analyzed two Pkd1-deletion mice (PN4) and four age-matched 
control kidneys, at the age of 1 month, as well as twelve Pkd1-deletion mice (PN40) and 12 age-matched wild 
type kidneys, at different time points after Pkd1 gene disruption. The kidneys were fixed in 4% formalin and 
embedded in paraffin. After de-paraffinization, sections were stained using standard procedures.21 All antibodies 
were incubated over night at 4°C and the antibody complexes were visualized using 0.04% diaminobenzidine-
tetra-hydrochloride (DAB) with 0.5% CuSO4 (brown precipitate) or 0.7% NiCl2 (black precipitate), except for 
α-SMA/AF (conjugated with alkaline phosphatase) that was incubated for one hour at room temperature and 
visualized by fast red. 
Antigen-retrieval was done for P-Smad2 and MMP-2 using citric acid buffer (0.01 M, pH 6.0) at 1000C for 
10 min, and for P-Smad1/5/8 and FSP-1 sections were incubated in Tris:EDTA (10:1 mM) at 1000C for 10 
min. Specificity of immunoreactive signals for TGFb was established by competition with recombinant hu-
man TGFb1 (Peprotech, London, UK); 10x and 100x surplus). For histological analyses kidney sections were 
stained with hematoxylin-eosin (HE) and Sirius red (stains total collagen).22  
An extensive detailed analysis of all stainings has been done by two individuals. In addition two other 
individuals also judged the stainings. For FSP-1, α-SMA and sirius red we randomly photographed six areas 
of the cortex and medulla at the magnification of 200x. FSP-1 was quantified by counting the percentage of 
FSP-1-positive cells. Between 500 and 900 epithelial and interstitial cells were counted per section; glomeruli 
were excluded. The areas stained for α-SMA and sirius red were quantified using software ImageJ (available at 
http://rsb.info.nih.gov/ij). The proportion of collagen, FSP-1 and α-SMA of the wild type and mutant mice were 
compared with an independent sample 2-tailed T-test.  A P-value of <0.05 (2 tailed) was considered significant.
Western blot
To quantify P-Smad2 expression we performed a western blotting on kidneys of 3 wild type and 3 C57Bl6/J-
Pkd1nl/nl mice at the age of 21 days. Tissues were homogenized using MagNALyser (Roche Diagnostics; 2 times 
20 seconds at 7000rpm) in RIPA buffer (50mM Tris HCL PH7.4, 150mM NaCl, 1mM EDTA) with 2mM NaF 
and 1mM Na2VO4 (Phosphatase inhibitors) and protease inhibitor cocktail (Roche, Woerden, The Netherlands). 
This was followed by 3 times 5 seconds sonification on ice.  RIPA buffer with 2 times detergent was added to 
the lysates to get final concentrations of 1x RIPA with 1%DOC, 1%NP40, 1%TritonX100, and incubated for 
45 min at 4°C. Finally, lysates were centrifuged 10 min at 14.000g and supernatants were used for the western; 
100 μg protein was loaded for each sample. Western blotting was performed as described previously.4 Blots 
were blocked by 0.25x SEA blocking buffer (Pierce, Rockford, USA) in PBS. Primary antibodies include anti-
α-tubulin (DM1A; CP06; 1:2000; mouse monoclonal antibody; Calbiochem, Amsterdam, The Netherlands) and 
P-Smad2/3 (1:10.000; rabbit polyclonal antibodies).18 Secondary antibodies include anti-IgG-rabbit (Fc) IRDye 
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800CW (1:7000; Tebu bio, Heerhugowaard, the Netherlands) and anti-IgG-mouse Dylight 680 (1:7000, Tebu 
bio, Heerhugowaard, the Netherlands). Blots were visualized and scanned using the Odyssey Infrared Imaging 
System (Li-Cor Biosciences). The values of wild type and mutant mice were compared with an independent 
sample 2-tailed T-test. A P-value of <0.05 (2-tailed) was considered significant.
mRNA Quantification
Transcript levels of matrix metalloproteinase-2 and 14 (MMP-2 and -14), Plasminogen activator inhibitor-1 
(PAI-1), collagen type 1 and EDA-fibronectin, were determined by Reverse Transcriptase Multiplex Ligation 
dependent Probe Amplification (RT-MLPA).  We analyzed 4 C57Bl6/J-Pkd1nl/nl and 3 wild type kidneys (21 
days old). In addition, 12 young induced Pkd1 deletion (PN4) and 12 control kidneys at two time points (13 and 
30 days after Pkd1 deletion) and  28 adult induced Pkd1 deletion (PN40) and 25 control kidneys at different 
time points (14 days and 1, 2, 3, and 4 months after Pkd1 deletion) were analyzed. The RT-MLPA reactions were 
performed as previously described.23,24  Briefly, kidneys were homogenized and total RNA was isolated. From an 
aliquot of 200-300 ng total RNA, cDNA was synthesized. Two separate hybridization reactions were performed 
with this cDNA. To each sample, MLPA probe mix and SALSA MLPA buffer were added (MRC-Holland, 
Amsterdam, the Netherlands), and the samples were incubated at 95°C  for 1 min followed by 60°C for 4 hours. 
Sequences of oligonucleotide probes, primers and competitors are availible at request. The ligation of the an-
nealed probes was performed at 54°C for 10-15 min. The ligase enzyme was inactivated by heating at 98°C for 
5 min, and the ligation products were amplified by PCR using SalsaTaq (Applied Biosystems, Nieuwekerk a/d 
Ijssel, the Netherlands). The amplified samples were mixed with Hi-Di Formamide containing GeneScan-500 
ROX size standard (Applied Biosystems, Nieuwekerk a/d Ijsel, the Netherlands) heated for 5 min at 95°C and 
run on a 3730 DNA analyzer (Applied Biosystems, Nieuwekerk a/d Ijsel, the Netherlands). Data were analyzed 
using GeneScan Analysis 3.5 and Microsoft Excel software. For situations in which off-scale signals needed 
to be reduced, competitor oligos were applied. The expression of the house keeping genes Ywhaz (tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) and Hprt (hypoxanthine 
guanine phosphoribosyl transferase) served as reference for gene expression. Peak ratios of the target genes and 
house keeping genes were calculated, and results of the mutant and wild-type kidneys were normalized to the 
median of wild type kidneys of the same age, which was set to 1. The MLPA values of the wild type and mutant 
mice were compared with an independent sample 2-tailed t-test. A p-value of <0.05 (2-tailed) was considered 
significant.
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Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a multi-system disorder 
characterized by progressive cyst formation in the kidneys. Serious complications of 
ADPKD are intracranial and aortic aneurysms. The condition is mainly caused by 
mutations in the PKD1 or PKD2 gene. We have carefully analyzed vascular remodeling 
in hypomorphic Pkd1nl/nl mouse model with dissecting aneurysms in the aorta. 
Quantitative real-time polymerase chain reaction revealed that in the aorta the expression 
of normal Pkd1 is reduced to approximately 26%. Using (immuno)histochemistry we 
have characterized the pathogenetic sequence for dissecting aneurysm formation. The 
aorta shows regions with accumulation of matrix components between the elastin 
lamellae. This is followed by increased numbers of smooth muscle cells and locally
weakening of the media. In the intima, accumulation of matrix components and 
detachment of endothelial cells from the elastin lamellae results in a tear. The 
combination of weak media and a tear in the intima leads to rupture of the vessel wall 
resulting in intramural bleeding. The Pkd1nl/nl mouse reveals that polycystin1 is 
implicated in maintenance of the vessel wall structural integrity, and it is a useful model 
for dissecting aneurysm formation studies. 
Introduction
Autosomal Dominant Polycystic Disease (ADPKD) is one of the most common genetic 
diseases. ADPKD affects 1 in 1000 individuals and is characterized by progressive 
development of renal cysts and an increased risk of aneurysm formation. The prevalence 
of cerebral aneurysms in ADPKD patients is approximately 10-fold higher than in the 
general population and about 27% among ADPKD patients with a family history for 
aneurysms.1,2 The few clinical studies done to determine the frequency of aortic 
aneurysms in ADPKD, suggest a prevalence varying from 1% to 10% in ADPKD 
patients.3–5 Furthermore, a gene expression profile study revealed a decrease of PKD1 
expression in dissected human aortas.6 ADPKD has been associated with mutations in the 
PKD1 or PKD2 gene, encoding the proteins polycystin-1 and polycystin-2. Both genes 
are expressed in the smooth muscle cells (SMCs) and endothelial cells (ECs) of the blood 
vessel.7–9 At present, however, hardly any histopathologic analyses on dissections and 
aneurysms in ADPKD have been performed. 
Several Pkd1 and Pkd2 knock-out mouse models have been generated, however knock-
out embryos die at embryonic days 13.5 to 14.5 from a primary cardiovascular defect.9–12 
These embryos show edema, focal vascular leaks, and hemorrhage. The fact that these 
mice die in utero withholds the possibility to study aneurysm formation in ADPKD. 
Recently, we have generated a Pkd1 hypomorphic mouse model, Pkd1nl/nl, with reduced 
Pkd1 transcripts in the kidneys.13 Pkd1nl/nl mice are viable, and the majority of the 
animals die within 1 to 2 months after birth. These mice show dissecting aneurysms and 
cysts in kidneys, liver, and pancreas, which is in line with the pathogenic features found 
in the human ADPKD phenotype.
Pkd1nl/nl mice are the first viable ADPKD mice with spontaneous dissecting aneurysm 
formation in the aorta enabling studies on vascular remodeling in ADPKD. In this study 
we have carefully characterized dissecting aneurysm formation in these hypomorphic 
mice. Reduced levels of Pkd1 transcripts measured in the aorta indicate a direct 
association between Pkd1 and vessel wall integrity.
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Results
Analysis of Aortic Pkd1 mRNA Levels
We used Pkd1nl/nl mice containing a loxP-flanked neomycin selection-cassette in intron 1 
of the Pkd1 gene. We previously have shown that a fragment of the neomycin cassette is 
incorporated in a fraction of the Pkd1 transcripts by alternative splicing in the kidneys, 
resulting in a frame shift and predicted to result in an early premature translation stop.13 
This results in a reduction of the normal Pkd1 expression. Here we determined the level 
of normal Pkd1 in the aortas of hypomorphic and wild type mice with a real-time PCR 
assay. In mutant mice, the expression of normal Pkd1 is reduced to approximately 26% in 
the aortas and 37% in the kidneys of the same mice (Figure 1A). The total Pkd1 
expression (normal plus mutant Pkd1) in the Pkd1nl/nl mice is about 1.5 and 2.7 times-fold 
increased in aorta and kidney, respectively (Figure 1B). In aortas of Pkd1nl/nl mice the ratio 
of normal versus total Pkd1 expression is approximately 0.13, indicating that only 13% of 
the total Pkd1 transcript is normal. The same ratio was found in the kidneys.
Figure 1. Quantitative real-time PCR analysis of renal and aortic RNA samples of wild type 
and Pkd1nl/nl mice. 
A, Expression of normal Pkd1 transcript. The 5’Pkd1 PCR amplifies normal Pkd1 transcripts. 
5’Pkd1 vs Hprt is normalized to the mean ratio of wild-type mice, which has been set to 1. The 
expression of normal Pkd1 transcript in the aorta and kidney of Pkd1nl/nl mice is reduced to 26% and 
37%, respectively. B, Total Pkd1 transcript. The 3’Pkd1 PCR amplifies both mutant and normal 
Pkd1 transcripts. 3’Pkd1 vs Hprt is normalized to the mean ratio of wild type mice, which has been 
set to 1. The total Pkd1 transcript is about 1.5 and 2.7 times increased in aorta and kidney of Pkd1nl/
nl mice, respectively. In both kidney and aorta, about 13% of the total transcript is normal.
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Figure 2. Dissecting aneurysms in Pkd1nl/nl mice. A–C, Hematoxylin Eosin. A, Progressive 
dissection with 2 pseudo lumens (asterisk) filled with blood. B, Local dissection with intramural 
bleeding (asterisk). Segment B did not show abnormalities (C1) whereas the surrounding region 
showed progressive media thickening (C2). D–H, Wild-type aorta: D, Hematoxylin Eosin; E, 
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Resorcin Fuchsin; F, Alcian blue; G, fibronectin; H, SM-actin. I–K, Sequential sections showing 
mild medial thickening: I, Resorcin Fuchsin; J, Alcian blue; K, fibronectin. The elastin lamellae are 
disjoined (arrow; I) showing accumulation of proteoglycans (J) and fibronectin (K) between the 
elastin lamellae (arrows). L–O, Progressive stages of medial degenerative changes in Pkd1nl/nl mice: 
L, Hematoxylin Eosin; M, Resorcin Fuchsin; N, Alcian blue; O, SM-actin. At more progressive 
regions, media thickening with increased SMCs between the elastin lamellae is found (L), however 
the elastin lamellae are still intact (M). At these regions proteoglycans are increased (N) whereas 
SM-actin is decreased (O; asterisks). Ki67 showed no proliferation (P), whereas the positive contorl 
(basal cells of the esophagus) did stain positive (arrow; P’). MMP-2 (Q) and TUNEL (R) were both 
negative in these regions, whereas the positive control was positive, (cystic kidney Q’) and (pros-
tate tissue R’), respectively. Bar=100mm.
Characterization of Aortic Pathology in Pkd1nl/nl Mice
Eight of the 9 examined Pkd1nl/nl mice showed 1 or more abnormalities with different 
severity at different regions in the descending thoracic and abdominal aorta. Dissections 
with intramural bleeding were detected in 5 mice. Five mice had progressive dissecting 
aneurysms showing pseudo lumens all over the descending aorta (3 mice; Figure 2A) or 
caudal mesenteric artery (2 mice). Two mice showed a local intramural bleeding (Figure 
2B). The dissections in the caudal mesenteric arteries were ruptured leading to retro-
peritoneal bleeding. One mouse showed local progressive medial thickening in the 
abdominal aorta without intramural bleeding. The volume of the vessel wall in the areas 
of these progressive dissections was significantly increased in both the thoracic and 
abdominal aorta compared with the wild type aortas of the same regions. However, the 
inner vessel lumen was not changed (Figure 3A and 3B).
The ascending aorta and segment B, which is located between the left carotid and the 
left subclavia in the aortic arch, were normal. One mouse showed media thickening in 
the whole area of the aortic arch and descending thoracic aorta except for segment B and 
the ascending aorta (Figure 2C). In these 2 normal regions SMCs seemed to keep their 
connection with the matrix, whereas the surrounding region of the aorta showed media 
thickening with disjoined elastin lamellae. 
In addition to dissecting aneurysms, all descending aortas studied contained normal 
vessel wall structure and incomplete dissections. Medial thickening was found in the 
thoracic aorta of 6 mice, in the abdominal aorta of 2 mice and intima thickening was found 
in the thoracic aorta of 1 mouse and in the abdominal aorta of 2 mice. The abnormalities 
found, were of varying pathological severity. This allowed us to describe the sequential 
order of events occurring in the media and intima, resulting in a dissecting aneurysm
Media Thickening in Pkd1nl/nl Aortas
The media of the aorta of wild type mice consists of 5 to 6 layers of SMCs alternated with 
concentric sheets of elastin lamellae (Figure 2D, 2E, and 2H). Surrounding the SMCs 
extracellular matrix molecules like proteoglycans and fibronectin are present (Figure 2F 
and 2G). Examination of elastin lamellae in Pkd1nl/nl aortas by Resorcin Fuchsin staining 
showed an increase in the space between the lamellae without any fragmentation of the 
lamellae (Figure 2I). The expression levels of proteoglycans and fibronectin were both 
notably increased in these regions (Figure 2J and 2K) compared with wild type aortas 
(Figure 2F and 2G). 
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Figure 3 Volume measurements of 
aortic lumen and vessel wall in 
thoracic (A) and abdominal aortas (B). 
The volume of vessel wall in both the 
thoracic and abdominal aortas is 
increased. The volume of the inner 
vascular lumens of wild-type mice is not 
significantly different from mutant mice. 
*P=0.05
The proteoglycans versican and perlecan have been shown to be increased in cultures of 
medial smooth muscle cells from tissue affected by abdominal aortic aneurysm.15 In our 
mouse model perlecan was increased whereas versican was absent in both wild type and 
mutant mice (Table). Using immunohistochemistry no MMP-2 and 9 expression was de-
tected in the wild type or Pkd1nl/nl aortas (Figure 2Q). Zymography, which is a more sensi-
tive method than immunohistochemistry, revealed none to a very low and similar MMP-2 
and MMP-9 expression in both, mutant and wild type, aortas (Figure 4). At other more 
progressive regions in the aortas, the elastin lamellae were more disjoined with an 
increased number of smooth muscle cells in between (Figure 2L). However, the elastin 
lamellae were still intact (Figure 2M).
The SMCs were disarranged with a low SM-actin expression (Figure 2O). Few SMCs 
had condensed nuclei, however these cells did not stain positive for TUNEL (Figure 2R). 
Macrophage staining did not reveal any immune-infiltrate in this region (Table). No 
accumulation of fibronectin was detected in this region. However, proteoglycans were 
still increased (Figure 2N). The distribution of collagen and fibrillin 1 in the vessel wall 
of Pkd1nl/nl mice was comparable to wild type mice. No calcification or expression of 
osteopontin was detected in all vessels analyzed (Table).
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Figure 4. MMP-2 and 9 expressions in Pkd1nl/nl and wild type aortas. 
Left panel: Pkd1nl/nl aortas of mouse 5499 and 5500 (Lane 1 and 2), wild type aorta of mouse 5508 
(Lane 3). Positive controls for MMP-2 and MMP-9 expression were NIH 3T3 fibroblast stimulated 
with 10ng/ml TNF alpha (lane 4) and bone marrow macrophages stimulated with 100ng/ml LPS 
in serum free medium or with 10% FCS (lane 5 and 6 respectively). A positive control for human 
MMP-2 and MMP-9 expressions was serum free medium of human fibrosarcoma cell line HT1080 
(lane 7). MMP-2 and MMP-9 are indicated by arrows. A lower molecular weight band for MMP-1 
and MMP-3 can be observed as well. Right panel: Pkd1nl/nl aortas of mouse 5510 and 5511 (Lane 2 
and 3), wild type aortas of mouse 5514 and 5515 (Lane 4 and 5). Positive control used was serum 
free medium of human fibrosarcoma cell line HT1080 (Lane 1).









SM-alpha-actin + +/- - -
Isolectin - - + +/-
Collagen I + + + +
Collagen III + + + +
Collagen + + + +
Fibrillin I + + + +
Elastin + +* + +*
Fibronectin + ++ + +
osteopontin - - - -
calcium deposition - - - -
perlecan + ++ - -
versican - - - -
proteoglycans + ++ - +/-
macrophages - - - -
MMP-2 - - - -
MMP-9 - - - -
Ki-76 - - - -
Tunel - - - -
*Elastin lamellae were diverged/broken. - indicates no expression.
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Intima Thickening in Pkd1nl/nl Aortas
The wild type intima consists of a single layer of flattened endothelial cells on a basal 
membrane and a subjacent elastin lamellae known as internal elastic lamina. Histological 
analysis of the intima of Pkd1nl/nl by Hematoxylin Eosin showed detachment of the ECs 
from the internal elastic lamina (Figure 5A and B). At these regions isolectin staining was 
decreased indicating a decreased number of ECs or decreased expression of this marker 
Figure 5. Histopathologic 
appearance of the intima in 
Pkd1nl/nl mice. 
A–G, Sequential sections showing 
different stages of intima 
degenerative changes in Pkd1nl/nl 
mice. ECs detach from the internal 
elastic lamellae (A) and the inter-
nal elastic lamina is less compact 
(B;arrows). At these regions 
isolectin is decreased (D) compared 
with control (C; arrows). At more se-
vere regions subendothelial 
thickening is found (E; arrow). At the 
entrance of the dissection, the elastin 
lamellae are broken (F; asterisks). 
A, E Hematoxylin Eosin; C, D 
isolectin; B, F Resorcin Fuchsin. 
Bar=100 mm.
Figure 6. Model for aneurysm formation in Pkd1 hypomorphic mice. A, Normal vessel wall. 
B, The SMCs produce an excessive amount of matrix components, which accumulate between the 
elastin lamellae. C, SMCs between the disjoined elastin lamellae proliferate increasing the media 
thickness. D, The endothelial cells detach from the elastin lamellae. E, The number of intima cells 
increases and the matrix components accumulate in the subendothelial region. F-H, The
combination of a weak aortic media and a tear in the intima leads to (partial) rupture of the vessel 
wall resulting in intramural bleeding.
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on ECs (Figure 5C and D). In other regions the subendothelial region was filled with 
proteoglycans and the cell numbers were increased (Figure 5E). However, the 
accumulation of proteoglycans is neither attributable to an increase in versican or 
perlecan nor did it coincide with increased fibronectin expression as observed in the
media thickening (Table). One of the mice showed a tear in the intima next to the 
degenerative changes within the media resulting into a progressive dissection all over the 
aorta (Figure 5F). At the entrance of dissection, fragmentation of the elastin lamellae was 
found, allowing the blood to spread through the aortic media. Despite substantial effort, 
we could not locate the exact site of rupture in the other animals. 
Dissecting Aneurysm
Abnormalities in the media and intima were identified in different regions of the aorta, 
indicating that the reduction of Pkd1 in both SMCs and ECs contributes to the formation 
of dissecting aneurysms by 2 processes, one in the media and the other in the intima. It is 
not clear whether the initial event of a dissecting aneurysm occurs in the intima or media. 
We hypothesize that on reducing the expression of polycystin1, the stability of the contact 
between SMCs and extracellular matrix molecules is reduced. This may disturb some 
cellular events in the SMCs resulting in a phenotypic change toward a more synthetic 
phenotype, which means that they produce more matrix components, which accumulate 
between the elastin lamellae, and start to hyperproliferate (Figure 6B). This results in an 
increased thickening of the media, which will become weaker (Figure 6C). In the intima 
the endothelial cells detach from the elastin lamellae (Figure 6D). The number of intima 
cells increases and the matrix components accumulate in the subendothelial region 
(Figure 6E). The final event allowing the blood to spread through the aortic media is the 
tear of the intima (Figure 6F and 6G). When present, next to the degenerative changes 
within the media, the resistance of the aortic wall to hemodynamic stress reduces, leading 
to dissection (Figure 6H).
Discussion
The Pkd1nl/nl mice provided a new model to study aortic dissecting aneurysm formation in 
ADPKD. It also confirmed the role of Pkd1 in dissecting aneurysm formation. Our mouse 
model represents a very severe phenotype of ADPKD with dissections in the aorta, 
probably due to the fact that the overall Pkd1 expression in the Pkd1nl/nl mice is lower than 
in human ADPKD patients. In patients one wild type Pkd1 allele is present, whereas in 
the aortas of these Pkd1nl/nl mice normal Pkd1 transcripts is approximately 75% reduced. 
All dissections were found in the descending aorta whereas the ascending aorta was nor-
mal. This is in line with the humane phenotype, as most dissections are found in the 
descending aorta of ADPKD patients.3–5 Although intracranial saccular aneurysms are 
more common in ADPKD than aortic aneurysms, no intracranial aneurysms were found 
in 3 Pkd1nl/nl mice at the age of 1 month (data not shown). Different regions of the aorta, 
indicating that the reduction of Pkd1 in both SMCs and ECs contributes to the formation 
of dissecting aneurysms by 2 processes, one in the media and the other in the intima. It is 
not clear whether the initial event of a dissecting aneurysm occurs in the intima or media. 
We hypothesize that on reducing the expression of polycystin1, the stability of the contact 
between SMCs and extracellular matrix molecules is reduced. This may disturb some 
cellular events in the SMCs resulting in a phenotypic change toward a more synthetic 
70
phenotype, which means that they produce more matrix components, which accumulate 
between the elastin lamellae, and start to hyperproliferate. This results in an increased 
thickening of the media, which will become weaker. In the intima the endothelial cells 
detach from the elastin lamellae. The number of intima cells increases and the matrix 
components accumulate in the subendothelial region. The final event allowing the blood 
to spread through the aortic media is the tear of the intima. When present, next to the 
degenerative changes within the media, the resistance of the aortic wall to hemodynamic 
stress reduces, leading to dissection.
Probably, intracranial aneurysms need more time to develop or the method used 
(immunohistochemistry) is not sensitive enough to detect small saccular aneurysms, or 
additional factors as elevated blood pressure are essential to develop these kind of 
aneurysms. Interestingly, in 6- to 9-month-old Pkd2 mice, Q. Qian et al observed 
macroscopic intracranial vascular complications after induction of hypertension.16 
A direct correlation between MMP-mediated elastin degradation and elastin calcification 
has been reported. Perivascular administration of CaCl2 to abdominal aortas induced 
calcification and degradation of elastin fibers.17 Focal linear calcifications were also 
detected in a mouse model with reduction of fibrillin-1 showing fragmentation of elastin 
lamellae and MMP-9 expression.18 Our data fit into this correlation. In our mouse model 
MMP-2 and MMP-9 expression was very low, comparable with wild type expression, 
and no elastin calcification or elastin degradation were found in the media thickening. In 
addition, we did not observe influx of inflammatory cells which are the main source of 
MMPs secretion. These properties of dissecting aneurysm formation in Pkd1nl/nl mice, 
therefore, seem to be distinct from other models.
Polycystin-1 has been found to be a component of large multiprotein complexes 
associated with cell-matrix contact at focal adhesions in cultures of renal epithelial cells. 
It is also associated with adherence junctions and desmosomes in confluent cultures of the 
renal epithelial cell line Madin-Darby canine kidney (MDCK).19–21 Polycystin-1 is also 
implicated in SMC elastin contact. The expression of Pkd1 is found in dense plaques, 
which are analogous to focal adhesions in epithelial cells and attach the intracellular 
contractile filaments of SMCs to the elastin lamellae.22,23 In our Pkd1nl/nl mice a widened 
space between the elastin lamellae was found, suggesting loss of contact between SMCs 
and elastin or other extra cellular matrix structures. Loss of physical contacts, and hence 
signals from these interactions, is associated with a phenotypic change toward a more 
synthetic phenotype of the SMCs.24 Furthermore, loss of the SMC-elastin interaction may 
increase SMC proliferation as elastin has a regulatory function controlling SMC 
proliferation.25 All these features are found in our Pkd1nl/nl mouse model, confirming this 
regulatory mechanism. Although we did not detect ki67-positive cells in the sections 
available for analysis, cell proliferation should have occurred because increased cell 
layers were present at certain stages of dissection formation and these cells did not stain 
for inflammatory cells. The decreased expression of SM-actin and increased expression 
of proteoglycans and fibronectin in the Pkd1nl/nl mouse model indicate a response toward 
a more synthetic phenotype.
Polycystin-1 might be involved in a SMC-matrix adhesion molecule complex, which 
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maintains a stable SMC phenotype and thereby maintaining the structural vessel wall 
integrity. Notably, no media thickening was found in segment B of the aortic arch of our 
mutant mice. The areas adjacent to segment B showed a progressive media thickening, 
suggesting a normal SMC-matrix contact in this segment. In wild type mice the media 
of this segment shows characteristics in which it differs from the rest of the aorta. It is 
negative for SM-actin and has extensive medial innervations. These SMCs have also a 
different embryonic origin compared with the descending aorta as it is derived from the 
fourth pharyngeal artery in the embryonic thoracic arterial tree.14,26 Interestingly, 
lowering the Pkd1 expression did not show any influence on the structure of this vessel 
segment. Pkd1 expression may not be critical in maintaining the structural vessel wall 
integrity in the aortic B-segment. 
Both polycystin-1 and 2 are probably involved in mechanosensing as they are localized in 
the primary cilia in renal cells.27 Polycystin-1 is also concentrated around centrioles and 
in particles along primary cilia of human umbilical vein endothelial cells (HUVECs).28 
Recently, monocilia were demonstrated on a subset of endothelial cells in low-shear 
regions.29 In addition, polycystin-1 has been shown to colocalize with platelet-endothelial 
cell adhesion molecule-1 (PECAM-1), a cell adhesion molecule also found to be 
involved in mechanosensing mechanism on the cell membrane.30,31 PECAM-1 also 
maintains adherens junction integrity and permeability. The latter function may be 
influenced by Pkd1 expression, as Pkd1 knock-outembryos showed increased micro-
vascular permeability at endothelium cell-cell junctions, edema, and hemorrhages.10,11 
All these factors may weaken the intima and alert the shear stress response, making the 
intima more prone to rupture.
Thus, lowering of Pkd1 transcription levels induces degenerative alterations in both the 
intima and media resulting into a dissecting aneurysm. However, intact regions of the 
aorta were still present in the Pkd1nl/nl mice and the overall construction of the aorta with 
regard to the elastin lamellae is normal. Furthermore, we did not found any abnormalities 
in these mice at the age of 1 week (data not shown). The elastin assembly may be 
independent of Pkd1 expression during development. Matrix components that are 
involved in elastin organization, like versican, and fibrillin-1, were also not altered 
compared with the wild-type aortas.32 This indicates that polycystin1 is probably not 
implicated in vessel wall development but rather maintains the structural integrity of the 
vasculature.
Methods
Animals and Tissue Preparation
The generation of Pkd1nl/nl mice has been described in detail by Lantinga-van Leeuwen et al.13 A loxP-flanked 
neomycin selection-cassette was inserted into intron 1 of the Pkd1 gene by homologous recombination, and a 
third loxP site was inserted in intron 11. Chimeric offspring were backcrossed with C57Bl/6Jico mice 3 to 6 
times. Histological analysis was performed on 9 Pkd1nl/nl (5 male and 4 female) and 5 (3 male and 2 female) 
control mice at the age of 1 month and 3 Pkd1nl/nl (1 male and 2 female) at the age of 1 week. The aortas, from 
aortic root to the bifurcation of the iliac arteries, were carefully dissected and fixed in 98% ethanol absolute with 
2% acetic acid or in 4% paraformaldehyde in 0.1 mol/L phosphate buffer (pH7.4). In 1 Pkd1nl/nl mouse only the 
abdominal aorta was not dissected. Fixed tissues were dehydrated in graded ethanol and xylene and 
embedded in paraffin. Five-micrometer sections of the complete ascending and descending aorta were 
completely mounted serially onto glass slides.
Antibodies
72
SM-a-actin (1A4) 1:2000 (Sigma), Collagen I and III 1:200 (Sanbio), Fibrillin-1 1: 500 (a generous gift from 
R. Mecham, Washington), Fibronectin 1:4000 (a generous gift from B.N. Bachera, Leiden, The Netherlands), 
Isolectin 1:20 (Sigma-Aldrich Chemie), Osteopontin 1:100 (a generous gift from L.W. Fisher, Bethesda, Md), 
Perlecan, Versican alpha and beta 1:20 (a generous gift from J.R. Hassell, Pittsburgh, Pa), Rabbit-anti-mouse 
Macrophage (AIA 31240) 1:200 (Accurate Chemical and scientific), matrix metalloproteinase (MMP)-2 Ab-4 
(75 to 7F7) 1:4 (Calbiochem), MMP-9 11A-5 (11A-5) 1: 100 (Neo Markers), Ki-67 1:3000 (Novocastra), 
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) 1:14 (Roche). Secondary 
antibodies: Rabbit-anti-mouse HRP 1:200, Swine-anti-rabbit HRP 1:200 (DAKO), Goat-anti-rabbit 1:50, 
Rabbit-peroxidase-antiperoxidase 1:250 (Nordic Immunologic Laboratories), mousebiotinylated (ABC-kit 
vectastain; Brunschwig Chemie).
Immunohistochemistry
After deparaffinization, sections were stained using standard procedures.14 The antibody complexes were 
visualized using 0.04% diaminobenzidine-tetra-hydrochloride (DAB; Sigma). Antigen retrieval was applied 
for fibronectin and ki67 staining and for monoclonal antibody 1A4 (SM-a-actin) a complex with the secondary 
antibody was prepared before incubation. Sections for fibronectin and ki67 staining were incubated in citric acid 
buffer (0.01 M, pH 6.0) at 98°C for 12 min for antigen-retrieval. The monoclonal 1A4 antibody (SM-a-actin) 
and secondary antibody rabbit-anti-mouse peroxidase (RAM-PO) were  first incubated to form 1A4-RAM-PO 
complex before adding it on sections following a previously described procedure.34
Histochemical staining
The following histological stainings were performed: Hacmatoxylin Eosin (HE), Resorcin Fuchsin (RF) for 
elastin lamellae, Alcian blue for staining glycosaminoglycans and thereby the proteoglycans, von Kossa and 
alizarin red for calcium deposition and Sirius red for collagen. The serial sections were alternately incubated 
for the different stainings. All (immuno) histochemical stainings, which were negative in the aortas, showed 
specific staining in positive control tissue.
Osteopontin stained positive in bronchus epithelial cells, von Kossa stained in trachea cartilage, alizarin red in 
bone, versican in heart valves, AIA 31240 in inflammatory tissue, Ki67 in basal cells of oesophagus, TUNEL 
in prostate tissue and MMPs in renal cystic tissue.
RNA Analysis
Complete aortas and kidneys of 5 control and 6 hypomorphic mice at the age of one month, were dissected and 
stored in liquid nitrogen until required. Tissues were first homogenized using a magNA lyser (Roche). Total 
RNA isolation was performed according to the manufacturer’s instructions (RNA-bee, AMS biotechnology). 
RNA was purified with nucleoSpin RNA II columns (Machery-Nagel) and cDNA was synthesized with Super-
Script II reverse transcriptase (Invitrogen). An aliquot of 100 ng RNA was used to generate cDNA. 
Quantitative real-time reverse transcriptase PCR analysis was performed using MyIQ technology (Biorad) and 
SYBR Green Supermix (Biorad). We developed two Pkd1 PCR primer pairs: the 5’ Pkd1 PCR specifically 
amplifies the normal Pkd1 transcript, and the 3’ Pkd1 PCR amplifies both mutant and normal Pkd1 transcripts. 
Primer sequences are described by Lantinga-van Leeuwen et al.13 Expression of the housekeeping gene Hprt 
(hypoxanthine guanine phosphoribosyl transferase) served as a reference for gene expression. All reactions 
were performed in triplicate.
Aortic Volume Measurements
To measure the volumes of aortic walls (including de dissection) and aortic lumens, we used the volume 
counting method according to Cavalieri.33 In short, the number of points on a grid hitting the tissue of interest 
on a series of sections was counted. Volumes could be calculated from the counted numbers by Cavalieri’s 
formula: V=∑[P].M-2.a.d. in this formula, V is the volume in mm3, ∑[P] is the total number of counted 
points, M is the magnification, a is the point area in mm2, and d is the distance between the counted sections 
in mm.
Zymography
Whole aortas of 4 mutant and 3 wild type mice were powdered in liquid nitrogen and a tissue extract was 
made in 50 mM Tris pH 7.7, 1.5 mM NaCl and 0.25% Triton X100. MMPs expression was analyzed by 
zymography on gelatin-containing polyacrylamide gels as described.35 Serum free medium of NIH 3T3 stimu-
lated with 10ng/ml TNF alpha for 24 hours and medium (serum free medium and medium with 10% FCS) of 
bone marrow macrophages stimulated with 100ng/ml LPS for 24 hours were used as a positive 
control for mouse MMP-2 and MMP-9 expression. Serum free medium of human fibrosarcoma cell line 
HT1080 was used for human MMP-2 and MMP-9.
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Statistics
The aortic volumes of the wild type and mutant mice were compared with an independent sample 2-tailed T-
test. A P value of <0.05 (2 tailed) was considered significant. All analyses were performed with the Statistical 
Package for Social Studies version 11.0 (SPSS Inc, Chicago, Ill).
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Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a multi-system disorder 
characterized by renal, hepatic and pancreatic cyst formation and cardiovascular 
complications. The condition is caused by mutations in the PKD1 or PKD2 gene. In mice 
with reduced expression of Pkd1 dissecting aneurysms with prominent media thickening 
have been seen. To study the effect of selective disruption of Pkd1 in vascular smooth 
muscle cells (SMCs), we have generated mice in which a floxed part of the Pkd1 gene 
was deleted by Cre under the control of the SM22 promotor (SM22-Pkd1del/del mice). Cre 
activity was confirmed by X-gal staining using lacZ expressing Cre reporter mice (R26R), 
and quantitative polymerase chain reaction indicated that in the aorta Pkd1 gene 
expression was strongly reduced while Pkd2 levels remained unaltered. 
Histopathological analysis revealed cyst formation in pancreas, liver and kidneys as the 
result of extra-vascular Cre activity in pancreatic ducts, bile ducts and in the glomerular 
Bowman’s capsule. Remarkably, we did not find any spontaneous gross structural blood 
vessel abnormalities in mice with somatic Pkd1 gene disruption in SMCs or simultaneous 
disruption of Pkd1 in SMCs and endothelial cells (ECs). Extensive isometric myographic 
analysis of the aorta did not reveal differences in response to KCl, acetylcholine, 
phenylephrin or serotonin, except for a significant increase in contractility induced by 
phenylephrin on arteries from 40 weeks old Pkd1del/+ germ-line mice. However, SM22-
Pkd1del/del mice significantly showed reduced decrease in heart rate upon Angiotensin II-
induced hypertension. The present findings further demonstrate in vivo, that adaptation to 
hypertension is altered in SM22-Pkd1del/del mice.
Introduction
Autosomal Dominant Polycystic Disease (ADPKD) is one of the most common inherited 
diseases, affecting 1:1000 individuals worldwide. The disease is characterized by the 
progressive kidney enlargement and destruction of the normal renal tissue by many fluid-
filled cysts, and progresses to end-stage renal failure (ESRF) in most patients. However, 
it is a slowly progressive disease with ESRF usually around the age of sixty.1 
Approximately 85% of cases are due to PKD1 mutations and in 15% the disease is caused 
by a mutation in PKD2.2 Both PKD1 and PKD2 are expressed in a variety of cell-types 
and tissues including renal epithelium, hepatic bile ducts, pancreatic ducts, vascular 
smooth muscle cells (SMCs), and endothelial cells (ECs).3-5 ADPKD is also associated 
with cysts in the liver and pancreas as well as cardiovascular complications such as 
hypertension and aneurysms.6 
Hypertension is very common in ADPKD, and occurs in the majority of patients before 
any substantial reduction in renal function is observed. Furthermore, hypertension occurs 
at a much earlier age in patients with ADPKD than in the general population. 
Hypertension is also associated with a rapid progression towards renal failure and 
increased cardiovascular complications (for review see7). The prevalence of cerebral 
aneurysms in ADPKD patients is approximately 10-fold higher than in the general 
population and about 27% among ADPKD patients with a family history for aneurysms.8;9 
Several mouse models have been established to study ADPKD using targeted disruption 
of the Pkd1 or Pkd2 gene. Homozygous Pkd1 and Pkd2 knock-out mice die in utero, 
around embryonic day 15, due to severe cystic disease, vascular defects and/or 
abnormalities of the placental labyrinth, while heterozygous Pkd1 knock-out mice showed 
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minimal renal cyst formation in adulthood.4;10-15 Furthermore, we described a Pkd1 mouse 
(hypomorphic) model, with low expression of Pkd1 showing progressive polycystic 
kidney disease and aortic dissecting aneurysms, indicating that Pkd1 is implicated in the 
structural integrity and function of the vasculature.16
In the hypomorphic Pkd1nl/nl mice a very prominent media thickening was seen in most 
of the animals analyzed. Since smooth muscle cells is the most abundant cell type in the 
media, we set out to study the effect of Pkd1 gene disruption in vascular smooth muscle 
cells on blood vessel function. To this aim we generated mutant mouse lines with a 
targeted disruption of the Pkd1 gene in SMCs, by crossing mice containing floxed Pkd1 
alleles with SM22Cre. We previously showed that Pkd1 gene disruption in vascular SMCs 
results in a reduced myogenic tone.18 Functional roles for the polycystins in mechano-
sensation have been proposed in ECs as well as SMCs. In endothelial cells, the proteins 
are involved in fluid shear stress sensing, thereby regulating calcium signalling and nitric 
oxide release. This affects vasodilatation in response to increased blood flow.19 In SMCs, 
the polycystins regulate the activity of the stretch-activated cation channels (SAC). In 
mice with reduced SMCs Pkd1 expression, SAC activity was decreased and the threshold 
pressure for myogenic contraction was significantly shifted to higher pressure values.18 
The ratio of polycystin1/polycystin2 regulates SACs activity since polycystin-2 inhibits 
channel opening, while  polycystin1 reverses this inhibition.18 It is likely that alterations 
in intracellular Ca2+ homeostasis contribute to the vascular phenotype in PKD.20;21 Here 
we show that disruption of the Pkd1 gene in these cells did not induce gross structural 
abnormalities in blood vessels, even not when Pkd1 was disrupted in endothelial cells, as 
well. However, an increase in blood pressure in SM22-Pkd1del/del mice, induced by 
Angiontensin II treatment, resulted in reduced heart rate adaptation.
Results 
Inactivation of Pkd1 in smooth muscle and endothelial cells does not result in gross 
structural blood vessel abnormalities.
To inactivate Pkd1 in SMCs, we crossed Pkd1del/lox mice with SM22Cre mice to yield 
SM22-Pkd1del/del. We carefully analyzed aortas of 6 SM22-Pkd1del/del mice (age 6 months) 
with Pkd1 gene disruption in SMCs but did not see any abnormalities (Figure 1A-C). 
Since the matrix metalloproteinase (MMP)-2 and -9, are key-activators in blood vessel 
remodeling we performed zymography to analyse MMP-2 and MMP-9 activity. No 
differences were observed between the different genotypes (not shown). Subsequently, we 
inactivated Pkd1 in both SMCs and ECs by crossing SM22-Pkd1del/del with Tie2-Pkd1del/del 
mice to yield SM22;Tie2-Pkd1del/del mice. We carefully analyzed aortas of 4 SM22;Tie2-
Pkd1del/del mice (age 6 months). Also these aortas were morphologically normal. As 
combined inactivation of Pkd1 in SMCs and ECs did not show any vascular phenotype, 
we did not further analyze the aortas of Tie2-Pkd1del/del mice with Cre activity only in ECs.
Inactivation of Pkd1 in SM22Cre expressing cells induces cysts in pancreas, liver and 
kidneys. 
All neonatal SM22-Pkd1del/del mice (age 3 and 4 days, n=7) showed a few large and small 
pancreatic cysts (Figure 1F) as well as dilated glomeruli in kidneys. The liver showed no 
cysts at this age. Most mice survived and were sacrificed at the age of 6 months, (n=10) 
large cysts were found in pancreas, liver and kidneys (Figure 1G-I). Cysts in pancreas 
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and liver were surrounded by spindle-like cells which were positive for α-smooth muscle 
actin (α-SMA, not shown) indicating infiltration of myofibroblasts (Figure 1, insets in 
G and H). The cysts were localized in groups, and few cysts were hyperplastic. In the 
pancreas, the cystic phenotype was more progressive compared to kidneys and liver, 
with larger numbers and size of cysts. Cysts in the pancreas and liver seem to originate 
from the pancreatic ducts and bile ducts, respectively, while no loss of pancreatic acini or 
hepatocytes in liver were detected.
In the kidneys, a few dilated glomeruli, 1-6 dilatations per section, were found in 
neonates at day 3. In 6 months old mice, large cysts were found and many of these cysts 
contained the glomerular tuft, which stained for the endothelial marker CD31, indicating 
Figure 1. Blood vessel structure and cyst formation in SM22-Pkd1del/del mice; the activity of 
Cre in SM22Cre and Tie2Cre mice. 
(A) Wild type aorta, HE staining. (B) SM22-Pkd1del/del aorta, HE staining. (C)SM22-Pkd1del/del 
aorta, elastin lammelae staining. (D) Cre induced LacZ activity in SMCs in aorta of 3-days-old 
SM22Cre;R26R mouse. (blue staining) (E) Tie2Cre induced LacZ activity in ECs (arrow) in aorta 
of 3-days-old Tie2Cre;R26R mouse  (blue staining) (F-I) Organs of SM22-Pkd1del/del mice (F) Large 
pancreatic cysts (arrows) in the abdomen of 3-days-old SM22-Pkd1del/del mouse (G) Small 
pancreatic cysts (arrow) and large cysts (asterisk). (H) Small (arrow) and large cysts (asterisk) 
in liver. Insets in G and H show fibrotic tissue around cysts. (I) Glomerular cysts (asterisk). Inset 
shows CD31 staining in glomerulus. (J-L) Recombination of lacZ (blue staining) under control 
of SM22 promotor in different organs of 3-days-old SM22Cre;R26R mice. (J) lacZ expression in 
pancreatic ducts (arrowhead). Inset show some acini cells express lacZ (arrow). (K) SM22Cre 
activity in liver. Bile ducts express lacZ (arrow and inset). (L) SM22Cre activity in kidney. The
parietal layer of Bowman`s capsule of mature glomeruli express lacZ (arrow). Cortical tubules 
show nonspecific staining (asterisk), which is also observed in control R26R mice (not shown). 
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the presence of glomerulus-derived-cysts (Figure 1I). Not all glomeruli were dilated and 
kidneys showed many normal glomeruli as well. None of the cysts stained positive for the 
nephron-segment-specific markers (megalin for proximal tubules, Tam Horsfall protein 
for distal tubules and loops of Henle and aquaporin-2 for collecting ducts). We also did 
not find dilatations of lymphatic or blood vessels, as determined by lyve-1, CD31 and 
α-SMA staining. 
Tie2-Pkd1del/del mice (n=13) did not show any abnormalities in the liver, kidneys, and 
pancreas at the age of 7, 8, 10, and 12 months. Only 2 mice showed 1 cyst in the liver (age 
7 and 10 months). The SM22;Tie2-Pkd1del/del mice with Cre activity in both SMCs and 
ECs (n=7) showed the same phenotype as the SM22-Pkd1del/del mice. Taken together, these 
results indicate that the Tie2-Pkd1del/del genotype does not cause gross structural 
abnormalities while the SM22-Pkd1del/del genotype is responsible for the cysts formation in 
the different organs of the SM22-Pkd1del/del and SM22;Tie2-Pkd1del/del mice.
Cre Activity in aortas of SM22Cre and Tie2Cre mice.   
To monitor the activity of Cre in the SM22Cre+ and Tie2Cre+ mice, we crossed these mice 
with a LacZ expressing Cre reporter mouse line, R26R.23 X-gal staining of  SM22Cre;R26R 
(age 3 days, n=2) aortas, revealed that efficient recombination of the reporter construct 
had occurred in SMCs in the media and the adventitia, resulting in expression of the 
LacZ-gene (Figure 1D). In Tie2Cre;R26R (age 3 days, n=1), LacZ expression was found 
in most ECs in the intima (Figure 1E). Pkd1 gene disruption by Cre was confirmed by 
PCR analysis of the DNA derived from the tails of mice carrying the Pkd1lox/+ alleles as 
well as SM22Cre or Tie2Cre  (Figure 2B). Even more, quantitative PCR revealed a strong 
reduction in Pkd1 mRNA levels in aorta’s of SM22-Pkd1del/del mice compared to SM22-
Pkd1del/+ and controls, while Pkd2 mRNA levels remained unaltered (Figure 2A).
Cre Activity in pancreas, liver and kidneys of SM22Cre and Tie2Cre Mice.   
To explain the phenotype of the SM22-Pkd1del/del mice, we analyzed Cre activity in the 
kidneys, liver, and pancreas in SM22Cre;R26R mice (age 3 days). X-gal staining was 
found in all three organs and it matched with the origin of cyst formation found in these 
organs in SM22-Pkd1del/del mice. In the pancreas, many serous acini and the ducts were 
positive for lacZ expression (Figure 1J). In the liver, expression was found in most bile 
ducts and in mesenchymal cells around the ducts (Figure 1K). In addition, blood cell 
precursors e.g. myeloblasts, myelocytes, granulocytes, and megakaryocytes were also 
positive for lacZ. Hepatocytes did not show lacZ expression. The kidneys showed lacZ 
expression in the parietal layer of Bowman`s capsule of mature glomeruli (Figure 1L). 
The control R26R mice, without the Cre transgene, did not show X-gal staining, except 
for a subset of proximal tubules. This was also found in the renal cortical tubules of 
SM22Cre;R26R and Tie2Cre;R26R, indicating nonspecific signal (Figure 1L). Smooth 
muscle cells of blood vessels in all organs were positive for X-gal. 
Deletion of Pkd1 under the control of Tie2 promotor did not result in a phenotype. 
Tie2Cre;R26R reporter mice, neonatal age 3 days, showed lacZ expression in endothelial 
cells in large vessels (Figure 1E), in capillaries, and in blood cell precursors (not shown), 
which is in line with previous reports.28
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Selective inactivation of Pkd1 in smooth muscle cells does not affect contractility
To analyze whether Pkd1 gene deletion has more subtle effects on vascular function,
several series of isometric myographic analyses were performed on aortas. First, 
heterozygous SM22-Pkd1del/+ mice and controls as well as homozygous SM22-Pkd1del/
del mice and their controls were analyzed at 11 weeks of age (Figures 3A-C). At this age 
the IC90 (internal diameter at 90 mm Hg pressure) is small, around 415 µm, and vaso-
constriction induced by phenylephrin is low (0.2 mN/mm at 10-5 M)(Figure 3C). No dif-
ferences were observed between the different genotypes (Figure 3C). We also found no 
differences between IC90 at vasoconstriction obtained with passive depolarization of the 
vessels with 80 mM KCl (PSS 80K), between activation curves obtained with serotonin 
or the vasoconstrictor U46619, and when looking at dilatation obtained with acetylcho-
line (Figures 3A, 3B).
Next series of measurements were performed on the heterozygous SM22-Pkd1del/+ mice 
and their controls, as well as the germ-line Pkd1del/+ (which carry a deletion allele in all 
cells) and wild-type controls, both performed on older mice, aged 40 weeks (Figures 3D-
I). The 40-weeks-old homozygous mutants SM22-Pkd1del/del were not available because 
of the cystic phenotype (see above). No differences were found between the IC90, with 
Figure 2. SM22Cre and Tie2Cre 
mediated recombination of the 
floxed Pkd1 allele. 
A) Pkd1 and Pkd2 mRNA lev-
els in aorta’s from SM22-Pkd1del/
del (n=13), SM22-Pkd1del/+  (n=9) or 
control (n=31) mice. Expression 
was normalized to the housekeeping 
gene. Results are presented as mean 
± SD of expression relative to the 
expression of  controls. B) Agarose 
gel analysis of PCR products 
amplified from genomic DNA 
isolated from tails of adult SM22-
Pkd1lox/wt,  Tie2-Pkd1lox/wt and 
Pkd1lox/wt. Three bands can be seen 
for both Tie2-Pkd1lox/wt and SM22-
Pkd1lox/wt mice; the wild type Pkd1 
allele (Pkd1wt), the floxed Pkd1 
allele (Pkd1lox) and the partially 
deleted Pkd1 (Pkd1del) indicating 
that floxed Pkd1 allele is deleted 
upon Cre expression in both mouse 
models. The intensity of the 366-bp 
deletion-specific PCR product is rel-
atively weak compared to the floxed 
or wild-type alleles since Cre-medi-
ated recombination 
occurred only in SMCs or ECs 
respectively. In control mice, 
without Cre, the deletion-specific 
product was absent.
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1029 ± 16 µm and 1053 ± 9 µm for SM22-Pkd1del/+ (n=10) and their controls (n=16) 
respectively (p=0.49), and with 967 ± 10 µm and 979 ± 10 µm for Pkd1del/+ (n=17) and 
their control wild types (n=12) respectively (p=0.79). The vasodilatation induced by ace-
tylcholine was not significantly different in both series of experiments (Figures 3D, 3G). 
The vasoconstriction induced by depolarization with 80 mM KCl was not different in 
both series (not shown). No difference was observed neither on the vasoconstriction in-
duced by serotonin (Figures 3E, 3H), nor on the one obtained with U46619 (not shown). 
The vasoconstriction induced by phenylephrin was not different between smooth muscle 
specific heterozygous SM22-Pkd1del/+ and their controls (Figure 3F). Interestingly, they 
were significantly higher in the germ-line Pkd1del/+ mice compared to wild-type (p=0.007 
at 3µM), as previously reported by Morel et al (2009) for 30 weeks old mice (Figure 3I).17 
Figure 3: Myographic analysis on aorta from 11 weeks and 40 weeks-old mice. (A, D, G) 
Dose-effect curve of the variation in tension, relative to precontracted tension, induced by differ-
ent concentrations of acetylcholine. Doses were added cumulatively after a precontraction with 1 
µm phenylephrin. Experiments were carried out on 11 weeks-old mice SM22-Pkd1del/del (n=22) and 
their controls (SM22Cre and Pkd1lox/lox, n=55)(A), and on 40 weeks-old SM22-Pkd1del/+ (n=10) and 
their controls (SM22Cre and Pkd1lox/+, n=16)(D), as well as with Pkd1del/+ germ-line mice (n=17) 
and their controls (wild type, n=12)(G). (B, E, H) Dose-effect curve of the variation in tension, 
relatively to resting tension, induced by various concentrations of serotonin. Doses were added 
cumulatively and experiments were carried out on the same mice as in A, D and G. (C, F, I) Dose-
effect curve of the variation in tension, relatively to resting tension, induced by various concentra-
tions of phenylephrin. Doses were added cumulatively and experiments were carried out on the 
same mice as in A, D, G.
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Increased blood pressure induces mild media thickening and impaired adjustment of 
heart rate in SM22-Pkd1del/del mice
Since the hypomorphic Pkd1nl/nl mice show a strong renal cystic phenotype, it is 
anticipated that those mice have an elevated blood pressure which could contribute to 
the vascular pathology. As baseline arterial pressure was not altered in SM22-Pkd1del/del 
mice compared to controls.18 We induced high blood pressure by infusion of Angiotensin 
II (AngII)(Figure 4). Histological analysis did not reveal structural differences between 
Angiotensin II-treated SM22-Pkd1del/del mice and controls (not shown). Interestingly, 
AngII-induced decrease in heart rate was significantly less pronounced in SM22-Pkd1del/del 
(p = 0.041, at 3 weeks), although the systolic pressure response was not different (Figures 
4A, 4B). 
Discussion
Previously, we analyzed a Pkd1 hypomorphic mouse model, Pkd1nl/nl, with reduced levels 
of Pkd1 transcripts in the aortas and kidneys.16 These mice showed dissecting aneurysm 
formation with very prominent abnormalities in the media and mild intima involvement. 
In addition, they have severe polycystic kidney disease.
In the current study, we generated mouse models to analyze the consequences of the 
specific deletion of Pkd1 in SMCs, which are the major component of the media. These 
mice, however, did not show any structural alterations of the aortic vessel wall in mice 
analyzed up to 6 months. Moreover, disruption of Pkd1 simultaneously in SMCs and ECs 
did not result in structural blood vessel alterations, even though the recombination levels 
were high in blood vessels as shown by the Cre reporter and by strongly reduced Pkd1 
mRNA levels. This is in agreement with early expression of the endogenous SM22 and 
Tie2 genes, around embryonic day 8.29;30 Our data indicate that Pkd1 gene disruption in 
SMCs alone and/or in ECs is not sufficient to induce gross structural abnormalities in the 
Figure 4: (A) Systolic blood pressure and (B) heart rate measured in SM22-Pkd1del/del  (n=6) and 
their controls (SM22Cre mice and Pkd1lox/lox littermates, n=18) at 1 to 4 weeks of angiotensin II 
infusion. Mean  ± SEM are shown. Difference in heart rate is significant at week 3 (p=0.041). The 
five measurements during each week were averaged. The pumps containing AngII were implanted 
between week 0 and week 1.
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aorta, suggesting that additional triggers are needed to induce or to accelerate the 
phenotype. For the renal cystic phenotype we previously showed that renal injury is a 
trigger that strongly accelerates polycystic kidney disease.31
Extensive isometric myographic analysis did also reveal that no difference in response to 
KCl, acetylcholine, phenylephrin, U46619 or serotonin was observed on young mice (11 
weeks) or on older mice (40 weeks), on heterozygous or on homozygous animals with a 
selective disruption of Pkd1 in smooth muscle cells. Only the 40 weeks old 
heterozygous Pkd1del/+ mice, which carry a deletion allele in all cells, show a significant 
increase in vascular contractility in response to phenylephrin. This increase has been 
previously reported in the same mutants aged 30 weeks, whereas at 12 and 20 weeks no 
differences were observed.17  Our results suggest that  heterozygous Pkd1 gene 
disruption in vascular SMCs is not sufficient to explain the increased phenylephrin 
response in Pkd1del/+ mice and that other cell types probably contribute to this vascular 
phenotype. In addition, the effect is building up over time.
Importantly, although we did not observe spontaneous structural alterations in the aorta’s 
of SM22-Pkd1del/del mice, these mice showed a decreased myogenic tone in resistance 
arteries.18 Interestingly, the ratio of polycystin-1/polycystin-2, which is disturbed in the 
deletion mutants, is of crucial importance for the regulation of stretch-activated ion 
channels (SACs) in arterial myocytes.18 Activation of SACs regulates myocyte 
contraction and thereby the vascular tone. When we implanted the angiotensin II releasing 
pumps to induce hypertension, the heart rate significantly slowed down in all genotypes.
This decrease in heart rate is the result of adaptation of the cardiac outflow to increased 
peripheral resistance and/or to the central nervous system effect of angiotensin.32;33 
Interestingly, in the homozygous SM22-Pkd1del/del mice, this decrease in heart rate is 
significantly less prominent compared to the control mice. Cardiac output (stroke volume 
x heart rate) is known to drop upon an increase in blood pressure, as for instance induced 
by angiotensin II infusion.34 However, according to the classical Guyton model (Guyton 
et al, 1972), without autoregulation (i.e. myogenic tone), cardiac output in response to 
hypertension is predicted to remain high.32;34 This model fits nicely with our  data as 
anticipated by a loss of myogenic tone in SM22-Pkd1del/del mice.18 Indeed, in these mice, 
the decrease in heart rate (i.e. cardiac output) is significantly less prominent compared to 
the control mice. Another possible mechanism of the hypertension-induced bradycardia 
may include a central effect through AT1 receptors in the central nervous system.33
Several other explanations could be given why without additional triggers the 
hypomorphic Pkd1nl/nl mice, and also Pkd1 knock-out mice, show structural abnormalities 
of the blood vessels at neonatal or embryonic stages respectively, while the SM22;Tie2-
Pkd1del/del mice do not.4;10;11;16 The genetic background may affect the process of blood 
vessel remodeling, since the complex mouse models used in this study consisted of a 
mixture of different genetic backgrounds. Furthermore, low Pkd1-expression in other 
cell types than SMCs and ECs in which Pkd1 is not disrupted in the SM22;Tie2-Pkd1del/del 
mice (for instance immune cells), may contribute to the process of aneurysm formation in 
Pkd1nl/nl mice, thereby accelerating the process. Therefore, it will be interesting to study 
the effects of increased blood pressure in SM22;Tie2-Pkd1del/del mice on full C57BL/6 
background, in future experiments.
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Although no spontaneous structural abnormalities of the vasculature were detected, we 
observed cyst formation in pancreas, liver, and kidneys when the Pkd1 gene was deleted 
under the control of SM22 promotor. Expression of LacZ matched with the sites of cyst 
formation and was found in pancreatic ducts and hepatic bile ducts, which are the origin 
of the cysts. In the kidneys, only glomerular cysts were found and recombination did 
occur in the parietal layer of Bowman’s capsule of glomeruli. It is known that Pkd1 is also 
expressed in pancreatic ducts, hepatic bile ducts, and Bowman’s capsule and thus 
coincides with the origin of the cysts as well.5;35;36 Also in ADPKD patients these cysts can 
be found. Our data indicate that the SM22 promoter fragment that regulates the 
expression of Cre is not exclusively expressed in vascular smooth muscle cells. 
Expression of the promoter in specific mesenchymal cells during development may 
explain the observed expression pattern.37
Despite the presence of large cysts, the function of the pancreas was not severely affected, 
as no loss of acini was found. In the liver, no loss of hepatocytes was noticed either. Fur-
thermore, the mutant kidneys showed many normal glomeruli beside the 
dilated ones. These results may explain why the mutant mice were able to survive for 
several months even with the presence of large cysts especially in the pancreas. 
The renal glomerular cystic phenotype was relatively mild and did not affect blood 
pressure. Glomerular cysts can also be found as part of ADPKD, predominantly in fetal 
kidneys but also in adult end-stage kidneys in addition to tubular cysts.38;39 In addition, 
glomerular cysts can develop as distinct entity, Glomerulocystic kidney disease (GCKD), 
or in the context of several other renal diseases.40-42 Also in Pkd1-mutant mouse models 
glomerular cysts have been observed. These cysts were only observed in Pkd1 knock-
out mice but not in hypomorphic mice that have low levels of Pkd1 gene expression, 
suggesting that total absence of Pkd1 is necessary to induce the formation of glomerular 
cysts.10;11;15;17;43;44 How these cysts arise is not entirely clear. Since Pkd1 is deleted in 
Bowman’s capsule, the suggested mechanism that urinary tract infections lead to increased 
pressure in Bowman’s space seems not very likely in SM22-Pkd1del/del mice.45 Defects in 
cilia signaling, cellular signaling, cell-cell and cell-matrix interactions, which have been 
observed in ADPKD tubular cysts, probably play a more important role. In addition, as 
polycystin-1 is known to affect migration and proliferation,46;47 the absence of Pkd1 might 
disturb the recruitment of podocytes from the glomerular parietal epithelial cells, which 
proliferate and migrate into the glomerular tuft and differentiate into podocytes.48
In conclusion, targeted deletion of Pkd1 in SMCs does not induce major structural blood 
vessel abnormalities, spontaneously, in mice. Increased blood pressure, however, 
revealed a mildly reduced adaptation of the heart-rate. It remains to be determined 




The generation of Pkd1del2-11 and Pkd1lox2-11 alleles has been described previously.17;22 The Pkd1lox 2-11 (Pkd1lox) 
allele contains two loxP sites inserted into intron 1 and 11. In the presence of the DNA recombinase Cre the 
loxP flanked sequence was deleted to form the Pkd1del2-11 (Pkd1del) allele. The floxed Pkd1 mice were crossed 
with SM22Cre mice (Tgln-Cre, Jackson laboratories, Bar Harbor, USA) to target smooth muscle cells (SMCs) 
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or with Tie2Cre mice (kindly provided by Dr. B. Arnold, Heidelberg, Germany) to target endothelial cells 
(ECs). This yielded SM22Cre+-Pkd1del/del mice (SM22-Pkd1del/del) and Tie2Cre+-Pkd1del/del mice (Tie2-Pkd1del/del). 
To generate SM22Cre+;Tie2Cre+-Pkd1del/del mice (SM22;Tie2-Pkd1del/del), SM22-Pkd1del/del mice were crossed 
with Tie2-Pkd1del/del mice. Littermates that were homozygous or heterozygous for the floxed Pkd1 gene and mice 
only expressing the Cre transgene, were used as controls. To analyze Cre activity in vivo, Tie2Cre and SM22Cre 
mice were crossed with the ROSA26 (R26R) LacZ-expressing Cre reporter mice.23 
All experiments using mice were approved according to the Dutch and French law and conform with the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). Approval was granted by a local ethics review board.
PCR for Pkd1 gene disruption in ECs and vascular SMCs
Genotypes were assessed by PCR analysis of tail genomic DNA using a reverse primer in intron 11 combined 
with a forward primer in intron 1 (del allele) or a forward primer in intron 11 (floxed and wild-type alleles) as 
described previously for genotyping of strains.22
Real-time quantitative PCR
Quantitative PCR was performed on mRNA isolated from aortas of 30 weeks old SM22-Pkd1del/del , SM22-Pkd1+/
del and control mice. For quantitative PCR (qPCR) analysis, primer sequences are as follow: Pkd1: Forward: GCC 
ATC CAG CAC TTC CTA GT,  Reverse: GAG AAG CCG ATC CAC ACA TC; Pkd2:Forward: AGGTGTTAG-
GACGGCTGCT,  Reverse: CCCTGTGGATCTCACTGTCC. qPCR data were normalized to the mouse Top1 
reference gene expression amplified using the following primers: Top1: Forward: GCCTCCATCACACTA-
CAGCA and Reverse: TTCGCTGGTACATTCTCATCA. qPCR data were analyzed using the LightCycler 480 
software release 1.5.0 and Excel program, as described previously.18
Immunohistochemistry
Histological analysis was performed on aortas (from aortic root to the bifurcation of the iliac arteries), pancreas, 
liver, and kidneys. The organs were dissected and fixed in 4% paraformaldehyde in 0.1 M sodium phosphate 
buffer for 24 hours. Fixed tissues were dehydrated in graded ethanol and xylene and embedded in paraffin. 
Sequential sections of 4μm were mounted onto superfrost-plus glass slides. After de-paraffinization, sections 
were stained using standard procedures.24 Sections were incubated in 0,1mg/ml pronase before incubation with 
CD31 (PECAM) and Lyve-1 antibodies. The monoclonal 1A4 antibody (alpha-SM-actin) and secondary an-
tibody rabbit-anti-mouse peroxidase (RAM-PO) were first incubated to form 1A4-RAM-PO complex before 
adding it on sections following a previously described procedure.25 The antibody complexes were visualized 
using 0.04% diaminobenzidine-tetra-hydrochloride (DAB). The following histochemical stainings were 
preformed; Hematoxylin Eosin (HE) and Resorcin Fuchsin (RF) for elastin lamellae.
 
Antibodies
The following primary antibodies were used: CD31 (1:50, BD Bioscience, Erembodegem, Belgium), lyve-
1(1:1000, Reliatech, Wolfenbüttel, Germany ), α-Smooth muscle actin (1A4, 1:2000, Sigma-Aldrich, 
Zwijndrecht, Netherlands), anti-megalin (1:500, Pathology, Leiden, The Netherlands),26 anti-Tamm Horsfall 
(Uromodulin) (1:3000, CAPEL, Durham, NC), anti-aquaporin-2 (1:300, Calbiochem, Amsterdam, The 
Netherlands). Secondary antibodies were: rabbit envision/ Horseradish Peroxidase (HRP) (undiluted; Dako, 
Heverlee, Belgium) and rabbit-anti-goat Ig/HRP (1:100, Dako, Heverlee, Belgium), goat anti-rat-biotin (1:200, 
BD Bioscience, Erembodegem, Belgium), goat serum (1:100, Brunschwig chemie, Amsterdam, The Nether-
lands), mouse-biotinylated (ABC-kit vectastain) (1:100, Brunschwig Chemie, Amsterdam, The Netherlands). 
X-Gal Staining
Tissues of 3 days old SM22Cre;ROSA26Cre  and Tie2Cre;ROSA26Cre mice and controls were stained whole 
mount for X-gal. Tissues were fixed for 2x 45 min in 0.2% glutaraldehyde, 1.5% paraformaldehyde, 2 mM 
MgCl2, 5 mM EGTA, 100 mM sodium phosphate pH 7.3. After fixation tissues were washed for 3x 20 min in 
wash solution (0.2% NP-40, 0.1% sodium deoxycholate, 2 mM MgCl2, 100 mM sodium phosphate pH 7.3). 
X-gal staining was performed for 48 hrs in 5 mM K3Fe(CN)6 ,5 mM K4Fe(CN)6,  1 mg/ml X-gal (solved in 
dimethylformamide), 0.2% NP-40, 0.1% sodium deoxycholate, 2 mM MgCl2, 100 mM sodium phosphate pH 
7.3. After washing for 3x 10 min in wash solution, tissues were post-fixed overnight in phosphate buffered 4% 
formaldehyde. Tissues were washed 2x 5 min in phosphate-buffered saline (PBS) and further processed for 
embedding by transferring them manually to 2x 60 min 50% ethanol,  2x 60 min 70% ethanol, 2x 60 min 95% 
ethanol, 2x 60 min 100% ethanol, 2x 60 min 100% 2-propanol. After warming to 60 0C the material was trans-
ferred to a pre-warmed mixture of 2-propanol/paraffin 1:1 for 2x 60 min and finally to paraffin for 3x 60 min. 
Sections of 4 μm were cut and counter stained with 0.1% Nuclear Fast Red and 5% Al2(SO4)3 for 5-10 seconds.
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Tail cuff measurements and osmotic pumps implantation
Systolic blood pressure and heart rate were measured by the tail cuff method (BP2000, Visitech), at 37°C to 
dilate the tail artery, 5 times weekly and averaged for each week. SM22-Pkd1del/del and control wild type mice 
(50% Pkd1lox/lox and 50% SM22Cre), 30 weeks old, were habituated to the measurement for 3 weeks before 
implantation of the pumps and then monitored during about 4 weeks. The osmotic pumps (Alzet model 2004) 
were implanted subcutaneously on the back of the animals and continuously delivered a dose of 0.61 mg/kg/
day of angiotensin II (Sigma) in PBS (Phosphate Buffer Saline). Systolic blood pressure and heart rate were 
recorded simultaneously. Significance of the 2 groups was tested with a permutation test (non parametric test) 
at a threshold of 5%; StatXact software).
To study the effects of elevated blood pressure on vessel structure, the thoracic aortas of control (Pkd1lox/lox 
and SM22Cre) and SM22-Pkd1del/del mice were observed. Fixation was done by perfusion with Bouin's fixative 
(formalin/picric acid) in the animal during 10 min and after removal from the animal in 10% neutral buffered 
formalin. Tissues were paraffin-embedded, sectioned, and stained with combined orcein (dark elastin staining) 
and picro-indigo-carmin (blue collagen staining). 
Wire-myography
Two-millimeter long segments of thoracic aorta were mounted on a wire-myograph (DMT, Aarhus, DK)
(isometric myography).27 Two steel wires (40 µm in diameter) were inserted into the artery lumen and fixed to a 
force transducer and a micrometer, respectively. A normalization procedure was used to evaluate the 
internal circumference that the aorta would have under a transmural pressure of 100 mmHg (IC100). To obtain 
a maximal and uniform response, all experiments were carried out at 90% of this internal circumference (IC90). 
Arteries were bathed in a physiological solution (PSS) composed of (in mM): NaCl 119; KCl 4.7; CaCl2 2.5; 
MgSO4 1.17; NaHCO3 25; KH2PO4 1.18; EDTA 0.027; glucose 5.5, oxygenated with a mixture of CO2 (5%) and 
O2 (95%), or the same PSS solution containing 80 mM KCl (NaCl substituted by KCl), named PSS 80K. Before 
each experiment, the contractility of the muscle was tested using the PSS 80K solution and then phenylephrin (1 
µM) in standard PSS. The integrity of the endothelium was assessed by verifying that at least a 70% relaxation 
effect was obtained with acetylcholine (5 µM) after a precontraction by phenylephrin (1 µM). For each mouse, 
between 2 to 4 responding aorta rings were measured and averaged, error bars indicates the standard error to the 
mean, n indicates the number of mice. Significance was tested with a permutation test (R; R Development Core 
Team: http://www.r-project.org/) at a threshold of 5% (*), 1% (**), and 1‰ (***). Cumulative dose response 
curves of phenylephrin, serotonin (5HT) and U46619 (thromboxan A2 agonist) were realized with extensive 
washout in between each curve. The cumulative dose response curve of acetylcholine was made after a 
precontraction with phenylephrin (1 µM). Experiments were performed on heterozygous SM22-Pkd1del/+ mice 
and controls (SM22Cre and Pkd1lox/+), homozygous SM22-Pkd1del/del mice and their controls (SM22Cre and Pk-
d1lox/lox) at 11 weeks, as well as heterozygous SM22-Pkd1del/+ mice and their controls and the germ-line Pkd1del/+ 
and wild types, on mice aged 40 weeks.
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common 
inherited disorder of the kidneys that is characterized by the growth of numerous fluid-
filled cysts in both kidneys. PKD cysts can enlarge the kidneys while replacing much of 
the normal structure, resulting in reduced kidney function and leading to kidney failure. 
Genes responsible for the disease are PKD1 and PKD2. The ADPKD patients show 
widespread variations in disease severity ranging from rare cases showing massively 
enlarged cystic kidneys in utero, through more typical presentation with end stage renal 
disease (ESRD) in the fifth or sixth decade, to cases with sufficient kidney function until 
old age. Several reasons are suggested for this variation, like the location of the mutation 
in the PKD1 and/or PKD2 gene, mutations in other modifying genes, and environmental 
factors.1,2 
The molecular and cellular mechanisms responsible for cyst formation are not known, 
but there are a lot of hypotheses. Cystogenesis is characterized by epithelial cell prolif-
eration, excessive secretion of solute and fluid into the cyst lumen and accumulation of 
matrix proteins in the renal interstitium, resulting into loss of functional renal tissue and 
interstitial fibrosis.
In this thesis we studied these mechanisms using predominantly a hypomorphic Pkd1 
mouse model (C57Bl6/J-Pkd1nl/nl), which is an orthologous model for polycystic kidney 
disease, with a rapidly progressive phenotype (chapter 2).3 It shows an early mortality 
which is either caused by rupture of dissecting aneurysms, which are found in large 
vessels like the aorta and mesenteric artery at the age of 3 to 4 weeks (chapter 4), or by 
renal failure as blood urea levels were moderately elevated at the same age. 
While the C57Bl6/J-Pkd1nl/nl live for a few weeks, the Pkd1nl/nl mice backcrossed on 129/
Ola background live longer and F1 mice of a homogeneous C57Bl6/J;129/Ola 
background have been analyzed up to one year. The C57Bl6/J;129/Ola -Pkd1nl/nl model 
shows the same progressive renal phenotype at 4 weeks as the C57Bl6/J-Pkd1nl/nl 
however, the former model shows a peak of the cystic index and kidney/body weight at 
the age of 4 to 5 weeks which then declines during a few weeks and increases again 
(H. Happé, personal communications). An explanation for the decreased cystic index 
might be that the cysts fold in at this age, thereby reducing the number of cysts. At these 
regions fibrotic tissue is formed. Indeed transforming growth factor beta (TGFb target 
genes, which are involved in fibrosis, also shows a peak at almost the same time point. 
The genetic background might also influence the development of aneurysms in these 
mice. Pkd1nl/nl mice, which had a 129/Ola origin, when backcrossed on C57Bl6 
background for 3 to 6 times show dissecting aneurysms in almost every mouse. However, 
further crossing on C57Bl6 or backcrossing on the 129/Ola background probably vanish 
or reduce the prevalence of this phenotype. The fact that the Pkd1nl/nl gene originates from 
129/Ola background, suggests also an epistatic effect of the flanking gene region, which 
become smaller upon backcrossing on C57Bl6. Indeed, ADPKD patients, even in the 
same family, do not all develop vessel abnormalities indicating that inactivation of the 
Pkd1 gene is not sufficient to initiate aneurysm formation and a certain combination of 
modifying genes must be present. 
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All mouse models homozygous for a Pkd1 deletion die around E15 presenting severe 
cystic kidneys, indicating that polycystin1(PC1) is required for normal kidney develop-
ment.4-7 The C57Bl6/J-Pkd1nl/nl mice, however, express low levels of Pkd1, are viable, and 
exhibit grossly normal kidney structure but with dilated proximal tubules at birth (chapter 
2). The first cysts develop from the fully mature proximal tubules around birth. This is 
followed by a phase of distal tubule and collecting duct cyst formation and progressive 
enlargement leading to renal failure. The same pattern might also occur in ADPKD 
patients. Prenatal ultrasound examination revealed hyperechogenic cortex that occurs in 
the third trimester. This hyperechogenic cortex is probably related to the presence of 
multiple microcysts within the renal cortex, which are most likely proximal tubules as the 
majority of the cortical tubules are proximal tubules.8 Indeed, one study reported proximal 
cysts in a hypomorphic PKD1 fetus.9
This pattern of nephron segment-specific cyst formation during nephrogenesis could be 
a reflection of Pkd1 expression. In immature proximal tubules, Pkd1 expression is high 
and declines progressively in mature proximal tubules but starts to increase in the loop 
of Henle, distal tubules, and collecting ducts, a pattern that persists in adult kidneys. This 
pattern is also found in other models of ADPKD or ARPKD and in humans.10-20
One of the most interesting features of ADPKD is cellular growth. Due to an unknown 
mechanism, a subset of epithelial cells escape the normal regulatory mechanism and start 
to grow and expand resulting in cyst formation.  A variety of studies indicate increased 
cell proliferation in the cystic kidneys of animal models and ADPKD patients. In the 
hypomorphic model, the C57Bl6/J-Pkd1nl/nl mice, the overall proliferation index in the 
renal epithelium at neonatal stages was comparable to wild type mice. Proliferation is 
much higher in the kidneys of 7- and 13 day-old mice compared to older mice, a 
phenomenon related to a developmental switch in kidney maturation.21 At this age 
proliferation is highest in the cortico-medullary region, which is a major growth zone 
for medullary structures and the region from which the majority of cysts are derived in 
C57Bl6/J-Pkd1nl/nl. Furthermore, conditional knockout models of Pkd1 have identified 
that inactivation of both alleles before 13 post-natal  days results in severe cystic disease, 
whereas inactivation after 14 post-natal days causes much milder disease.21,22 Beside the 
developmental switch, renal injury seems to increase proliferation and increase cystic 
index of conditional knockout Pkd1 models. This phenomenon coincides with aberrant 
planar cell polarity and increased Hippo signaling, both of which are also involved in 
tumourigenesis.23,24 
Beside proliferation, another driving force for cyst enlargement is transepithelial fluid 
and Cl- secretion mediated by NKCC1 and CFTR.25 In cystic epithelial cells chloride 
enters across basolateral NKCC1 cotransporters, driven by the sodium gradient generated 
by basolateral Na-K-ATPase, and exits across apical protein kinase A (PKA)-stimulated 
cystic fibrosis transmembrane conductance regulator (CFTR). Accumulation of chloride 
within the cyst lumen drives sodium and water secretion down transepithelial potential 
and osmotic gradients. In C57Bl6/J-Pkd1nl/nl mice, the expression pattern of NKCC1 in 
cystic kidneys is similar to the pattern observed in wild type kidneys with a relatively 
strong expression in proximal tubule-derived cysts, but only weak expression in cysts 
derived from distal tubules and collecting ducts (chapter 2). The fact that in this mouse 
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model, the first cysts are derived from the proximal tubules, suggests that transepithelial 
fluid and Cl- secretion is important in cyst formation at younger ages.
In addition to cysts formation, excessive fibrotic tissue is responsible for the loss of normal 
renal tissue. We show that TGFb signaling, the major fibrogenic cytokine, is increased in 
C57Bl6/J-Pkd1nl/nl mice during cyst expansion (chapter 3).26 Cytoplasmic TGFb 
expression and nuclear localization of P-Smad2 were detected in cystic epithelial cells 
as well as in interstitial cells suggesting that both cell types synthesize and respond to 
TGFb. This was accompanied by increased matrix synthesis as well as inadequate matrix 
degradation detected by increased synthesis of collagen, fibronectin, PAI-1 and MMP’s, 
suggesting a complex regulation of matrix remodeling with an imbalance towards 
accumulation of matrix proteins. Targeting TGFb by knocking out Alk-5, a gene 
encoding a TGFb receptor, in a Pkd1 conditional knock-out mice did not significantly 
prevent the expressing of the TGFb target genes (W. Leonhard, personal communication). 
This suggests that this pathway can still be activated via an alternative way; therefore 
inhibiting more than one target in this pathway is essential to retard or inhibit fibrosis.
Apart from the cyst formation in the kidneys, the Pkd1nl/nl mice, depending on genetic 
background, provide also a model to study aortic dissecting aneurysm formation in 
ADPKD, confirming the role of Pkd1 in dissecting aneurysm formation (chapter 4).27 Our 
mouse model represents a very severe phenotype of ADPKD with dissections in the aorta. 
We hypothesize that upon reducing the expression of PC1, the stability of the contact 
between smooth muscle cells (SMC) and extracellular matrix molecules is reduced. This 
may disturb some cellular events in the SMCs and endothelial cells (EC) resulting in cell 
proliferation and increased extracellular matrix synthesis, which accumulate between the 
elastin lamellae and weaken the vessel wall. Finally, the vessel wall tears leading to dis-
section. However, intact regions of the aorta were still present and the overall construc-
tion of the aorta with regard to the elastin lamellae was normal. This indicates that PC1 
is probably not implicated in vessel wall development but rather maintains the structural 
integrity of the vasculature.
We further analyzed the consequences of the specific deletion of Pkd1 in SMCs (SM22-
Pkd1del/del), which are the major component of the media (chapter 5).28 These mice, 
however, did not show any structural alterations of the aortic vessel wall. Moreover, 
disruption of Pkd1 simultaneously in SMCs and ECs (SM22;Tie2-Pkd1del/del) did not result 
in structural blood vessel alterations, even though the recombination levels were high in 
blood vessels as shown by the Cre reporter and by strongly reduced Pkd1 mRNA levels. 
These data suggest that additional triggers are needed to induce or to accelerate the 
phenotype. We can think of several explanations why the C57Bl6/J-Pkd1nl/nl mice and 
Pkd1 knock-out mice, show structural abnormalities of the blood vessels, while the 
SM22;Tie2-Pkd1del/del mice do not, like the influence of the different genetic background 
of mouse models used and contribution of other cell types than SMCs and ECs in which 
Pkd1 is not disrupted in the SM22;Tie2-Pkd1del/del mice. 
Although we did not observe spontaneous structural alterations in the aorta’s of SM22-
Pkd1del/del mice, these mice showed a decreased myogenic tone in resistance arteries. 
Interestingly, the ratio of PC1/PC2, which is disturbed in the mutants, is of crucial 
97
importance for the regulation of stretch-activated ion channels (SACs) in arterial 
myocytes. Activation of SACs regulates myocyte contraction and thereby the vascular 
tone.29 When we implanted angiotensin II releasing pumps to induce hypertension, the 
heart rate significantly slowed down in all genotypes. This decrease in heart rate is the 
result of adaptation of the cardiac outflow to increased peripheral resistance and/or to the 
central nervous system effect of angiotensin. Interestingly, AngII-induced decrease in 
heart rate was significantly less pronounced in SM22-Pkd1del/del. According to the classical 
Guyton model, without autoregulation (i.e. myogenic tone), cardiac output in response to 
hypertension is predicted to remain high.30 This model fits nicely with our data as antici-
pated by a loss of myogenic tone in SM22-Pkd1del/del mice.29
The SM22-Pkd1del/del provides a model to study other extra-renal manifestations of 
ADPKD as we observed cyst formation in pancreas, liver, and kidneys. Expression of 
LacZ matched with the sites of cyst formation and was found in pancreatic ducts and 
hepatic bile ducts, which are the origin of the cysts. In the kidneys, only glomerular cysts 
were found and recombination did occur in the parietal layer of Bowman’s capsule of 
glomeruli. Glomerular cysts can also be found as part of ADPKD, predominantly in fetal 
kidneys but also in adult end-stage kidneys in addition to tubular cysts. In Pkd1 mutant 
mouse models glomerular cysts were only observed in Pkd1 knock-out mice but not in 
hypomorphic mice that have low levels of Pkd1 gene expression, suggesting that total 
absence of Pkd1 is necessary to induce the formation of glomerular cysts. How cysts 
arise in SM22-Pkd1del/del is not entirely clear. Defects in cilia signaling, cellular signaling, 
cell-cell and cell-matrix interactions, which have been observed in ADPKD tubular cysts, 
probably play an important role. In addition, as PC1 is known to affect migration and 
proliferation, the absence of Pkd1 might disturb the recruitment of podocytes from the 
glomerular parietal epithelial cells, which proliferate and migrate into the glomerular tuft 
and differentiate into podocytes.31
Significant progress has been made over the last few years towards a better understanding 
of the pathogenesis of ADPKD. Our mouse models and data contribute by describing and 
analyzing cyst and aneurysm formation in mouse models of PKD. Polycystins are 
suggested to be involved in a variety of cellular functions. This is confirmed by the 
different processes which are deregulated upon mutation in a PKD gene, like 
proliferation, ion channel expression, extracellular matrix production and cilia 
mechano-sensing. Therefore, a multi-target targeted approach is crucial to slow down 
cyst formation. Indeed, curcumin, which has a beneficial effect on a wide variety of inter 
and intracellular signaling pathways, many of which are involved in cysts formation, 
seems to retard renal failure.32 
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Autosomaal dominant polycysteus nier ziekte (ADPKD) is een veel voorkomende 
erfelijke nierziekte met een prevalentie van 1:400-1:1000. Patiënten hebben vele 
blaasjes gevuld met vocht (Cysten) in de nieren. De afmetingen hiervan kunnen variëren 
van minder dan 1 mm tot 1 cm. Naarmate deze blaasjes groeien, zullen zij het 
functioneren van de nieren bemoeilijken en samen met verbindweefseling uiteindelijk 
leiden tot chronisch nierfalen. De meeste patiënten bereiken het eind stadium van 
nierfalen in het 5de of 6de decennium en hebben uiteindelijk nierdialyse nodig. 
Daarnaast, kunnen deze patiënten ook lijden aan andere complicaties, zoals cysten in de 
lever, aneurysmata in de arteriële bloedvaten (aandoening waarbij de wand van de 
bloedvaten zwak wordt en kan scheuren) en hoge bloeddruk. De oorzaak van cystenieren 
is een defect van de genen PKD1 of PKD2. Deze genen regelen de aanmaak van de 
eiwitten polycystine-1 en polycystine-2 (PC1 en PC2). Deze eiwitten spelen een rol onder 
andere bij cel-cel en cel-matrix contacten en signaaloverdracht waardoor ze opbouw van 
de het weefsel onderhouden. Wanneer de PKD genen niet goed zijn, dan zal er minder 
of zullen er afwijkende eiwitten aanwezig zijn. Daardoor kunnen de eiwitten hun functie 
niet meer voldoende uitvoeren en worden de cellen in de nierbuisjes ontregeld, 1) de 
cellen delen nu vaker, zodat er meer cellen ontstaan 2), sommige zouten en vloeistoffen 
worden de verkeerde richting opgepompt zodat de cysten groter worden, 3) en er zetten 
zich meer eiwitten aan de onderkant van deze cellen af, waardoor er meer bindweefsel 
ontstaat. Deze processen zorgen er voor dat de smalle buisjes van de nefron verwijden en 
er ontstaan cysten.
Een aantal aspecten van de ziekte hebben we in verschillende muismodellen bestudeerd, 
namelijk in muizen waarin we het Pkd1 gen specifiek in niercellen hebben uitgeschakeld, 
en muizen waarin in alle lichaamscellen een te lage activiteit van dit gen is.
In hoofdstuk 2 is de cysten ontwikkeling bestudeerd in het Pkd1 muis model met een 
zeer lage genactiviteit in alle cellen van alle organen. De celdeling, celdood, aanmaak 
van eiwitten tussen de cellen en ionen kanalen die de vochtophoping in de cysten stim-
uleren zijn bestudeerd. Dit muis model toont een snelle progressieve ziekte verloop met 
weinig bindweefsel. Celdeling en celdood zijn niet verhoogd vergeleken met de gezonde 
muizen.
In hoofdstuk 3 wordt de relatie van TGF-, een belangrijk eiwit dat de aanmaak van 
bindweefsel reguleert, bestudeerd in verschillende muismodellen met PKD. TGFb 
aanmaak en activatie van de signaaltransductie route is verhoogd in de milde (weinig 
cysten, maar soms grote cysten) en in progressieve fase (een groot gedeelte van de nier 
bestaat uit cysten) van cystenieren. In het begin fase, waarbij de meeste cysten klein zijn, 
is dit eiwit niet erg actief. 
Behalve nierfalen lijdt 1 tot 10% van de ADPKD patiënten ook aan aneurysmata. Dit is 
een aandoening van de vaten waarbij de vaatwand zwak wordt en kan scheuren. 
Patiënten overlijden dan aan interne bloedingen. Het verlagen van de PC1 in de hoofd-
slagader (aorta) ontregelt de cellen in de vaatwand waardoor dit zwak wordt en scheurt. 
In hoofdstuk 4 wordt deze aandoening in hetzelfde muismodel als in hoofdstuk 2, 
bestudeerd. Deze studie toont een directe relatie tussen de Pkd1 en vaatwand behoud.
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In de vaatwand zijn er voornamelijk twee soorten cellen, endotheel cellen voor de 
binnenbekleding van de vaatwand en gladde spiercellen binnen in de vaatwand. In 
hoofdstuk 5, is PC1 alleen in de gladde spieren verlaagd. Heel opmerkelijk, leidt dit niet 
tot veranderingen in de vaatwand maar ontstaan er cysten in de alvleesklier, lever en 
nieren. Wanneer Pkd1 werd verlaagd in de endotheel cellen en in gladde spier cellen 
samen, leidde dat ook niet in duidelijk afwijkingen in de vaatwandstructuur. Als volgende 
stap werd in deze muizen de bloeddruk verhoogd door medicatie (Angiotensine II). In de 
gezonde situatie wordt de hartslag verlaagd als reactie op de hogere bloeddruk, maar in 
deze mutant muizen werd de hartslag minder verlaagd dan in de gezonde situatie. Dit 
toont aan dat aanpassingen van de hartslag aan de bloeddruk is verstoord in deze muizen. 
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